deoxycytidine has been researched along with Invasiveness, Neoplasm in 400 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.25) | 18.2507 |
| 2000's | 94 (23.50) | 29.6817 |
| 2010's | 249 (62.25) | 24.3611 |
| 2020's | 56 (14.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grobet-Jeandin, E; Pinar, U; Rouprêt, M | 1 |
| Chen, D; Chen, F; Dong, L; Liu, D; Long, J; Wan, F; Wang, Y | 1 |
| Deng, L; Deng, Q; He, X; Lei, QY; Liu, C; Liu, S; Liu, Y; Lv, J; Qiang, J; Shao, ZM; Wang, D; Xia, J; Yu, Z; Zhang, L; Zhang, XY; Zhao, B; Zhou, L | 1 |
| Black, PC; Roumiguié, M | 1 |
| Chen, D; Chen, Q; He, C; Hu, P; Hu, Y; Huang, K; Huang, M; Niu, Y; Tang, J; Wang, C; Wang, F; Xu, F; Zeng, Z; Zhao, G; Zhao, Y | 1 |
| Fujii, T; Gyoten, K; Hayasaki, A; Iizawa, Y; Isaji, S; Kishiwada, M; Komatsubara, H; Kuriyama, N; Maeda, K; Mizuno, S; Murata, Y; Nakagawa, Y; Noguchi, D; Sakurai, H; Shinkai, T; Tanemura, A | 1 |
| Cleves, A; Dahm, P; Han, MA; Hwang, EC; Hwang, JE; Jung, JH; Maisch, P; Narayan, V | 1 |
| Aggen, D; Al-Ahmadie, H; Apollo, A; Bajorin, DF; Balar, AV; Bochner, BH; Boswell, A; Cha, EK; Donahue, TF; Donat, SM; Durdin, TD; Folefac, E; Francese, K; Funt, SA; Goh, AC; Herr, HW; Hettich, G; Huang, WC; Iyer, G; Jihad, M; Kamradt, J; Khalil, M; Lash, B; Lattanzi, M; Lee, CH; McCoy, AS; McHugh, D; Mortazavi, A; Ostrovnaya, I; Pietzak, E; Quinlan, C; Ratna, N; Regazzi, A; Rosenberg, JE; Teo, MY; Truong, H; Whiting, K; Yang, Y; Zimmerman, D | 1 |
| Niu, X; Wang, T; Zhong, B | 1 |
| Aron, M; Brummelhuis, ISG; Chau, A; Cutie, CJ; Daneshmand, S; Keegan, KA; Maffeo, JC; Pohar, KS; Raybold, B; Reynolds, DL; Steinberg, GD; Witjes, JA | 1 |
| Laukhtina, E; Shariat, SF | 1 |
| Kumar, S; Pareek, T; Parmar, K; Sharma, AP | 1 |
| Hirata, H; Ito, H; Kobayashi, K; Matsumoto, H; Matsuyama, H; Misumi, T; Nagao, K | 1 |
| Hu, X; Li, Y; Tong, S | 1 |
| Aydin, AM; Cheriyan, SK; Gilbert, SM; Hajiran, A; Jain, R; Li, R; Peyton, CC; Poch, MA; Reich, R; Sexton, WJ; Spiess, PE; Yu, A; Zemp, L; Zhang, J | 1 |
| Gellhaus, PT; Martin, AC; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Richards, J; Steinberg, RL | 1 |
| Kates, M; Rodriguez, KM | 1 |
| Cheng, HH; Dash, A; Garcia, J; Gore, JL; Holt, SK; Lam, HM; Lin, D; Makrakis, D; Montgomery, B; Mostaghel, E; Nelson, P; Porter, MP; Roudier, MP; Schade, G; Schweizer, M; Vakar-Lopez, F; Wang, Y; Winters, B; Wright, JL; Yu, EY; Zhang, X | 1 |
| O'Donnell, MA; Packiam, VT; Steinberg, RL | 1 |
| Mellema, JJ; van der Heijden, MS; van Rhijn, BWG | 1 |
| Alva, AS; Bangs, R; Bastos, BR; Daneshmand, S; Flaig, TW; Fowles, JS; Goldkorn, A; Gustafson, DL; Lerner, SP; Lucia, MS; MacVicar, GR; McConkey, DJ; Milowsky, MI; Plets, M; Tangen, CM; Theodorescu, D; Thompson, IM | 1 |
| Achkar, BE; Bhardwaj, N; Brody, R; Cabal, R; Cetnar, JP; Chan, KG; D'Souza, A; Daneshmand, S; Dorff, TB; Ellis, E; Galsky, MD; Gnjatic, S; Gogerly-Moragoda, M; Gonzalez-Kozlova, E; Haines, GK; Horwitz, A; Ioannou, G; Izadmehr, S; Jun, T; Kelly, G; Kim-Schulze, S; Kinoshita, Y; Kyriakopoulos, C; Lewis, S; Mamtani, R; Mehrazin, R; Mouw, KW; Neil, BO; Nie, K; Nose, Y; Pal, SK; Samstein, RM; Sebra, R; Sfakianos, J; Wang, L; Xie, H; Yu, M; Zhao, Q; Zhu, J | 1 |
| Hackman, RM; Mackenzie, GG; Penso, NEC; Wang, Y; Wei, R | 1 |
| Bracco, OL; Frenkl, T; Freshwater, T; Keefe, S; Li, H; Li, M; Perini, R; Valiathan, C | 1 |
| Cheung, WY; Gill, S; Kim, CA; Kong, S; Spratlin, J; Tsang, ES; Xu, Y | 1 |
| Ariake, K; Mitachi, K; Motoi, F; Unno, M | 1 |
| Haas, CR; McKiernan, JM | 1 |
| Brooks, NA; O'Donnell, MA | 1 |
| Bivalacqua, TJ; Brooks, N; Crump, T; Daniels, MJ; DeWolf, WC; Hyndman, ME; Kamat, AM; Kates, M; Lamm, DL; Mott, SL; Nagaraju, S; Nepple, KG; O'Donnell, MA; Rao, MY; Steinberg, RL; Thomas, LJ; Vitale, A; Wang, J | 1 |
| Abu Hilal, M; Alseidi, A; Bassi, C; Besselink, MG; Bolm, L; Busch, OR; De Pastena, M; Del Chiaro, M; Gill, AJ; Groen, JV; Groot Koerkamp, B; Groot, VP; Halimi, A; He, J; Jang, JY; Keck, T; Malleo, G; Marchegiani, G; Mieog, JS; Mittal, A; Samra, JS; Steyerberg, EW; Strijker, M; Suhool, A; van Eijck, CH; van Roessel, S; Wolfgang, CL; Zarantonello, L | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Endo, I; Kumamoto, T; Matsuyama, R; Murakami, T; Sawada, Y; Tsuchiya, N; Yabushita, Y | 1 |
| Aasbrenn, M; Abd El-Aty, AM; Abdu, A; Abraha, HB; Achour, A; Acquaroni, M; Addeo, P; Agback, P; Agback, T; Al-Alwan, M; Al-Mazrou, A; Al-Mohanna, F; Aliste, M; Almquist, J; Andel, J; Ando, M; Angelov, A; Annuar, MSM; Antwi, K; Arroliga, AC; Arruda, SLM; Asch, SM; Averous, G; Ayaz, S; Ayer, GB; Bachellier, P; Ball, S; Banijamali, AR; Barden, TC; Bartoncini, S; Bedanie, G; Bellò, M; Benić, F; Berhe, GG; Bertiger, G; Beumer, JH; Bhandari, B; Bond, DS; Boules, M; Braüner Christensen, J; Brown-Johnson, C; Burgstaller, S; Cao, L; Capasso, C; Carlevato, R; Carvalho, AE; Ceci, F; Chagas, ATA; Chavan, SG; Chen, AP; Chen, HC; Chen, J; Chen, Q; Chen, Y; Chen, YF; Christ, ER; Chu, CW; Covey, JM; Coyne, GO'; Cristea, MC; Currie, MG; Dahdal, DN; Dai, L; Dang, Z; de Abreu, NL; de Carvalho, KMB; de la Plaza Llamas, R; Deandreis, D; Del Prete, S; Dennis, JA; Deur, J; Díaz Candelas, DA; Divyapriya, G; Djanani, A; Dodig, D; Doki, Y; Doroshow, JH; Dos Santos, RC; Durairaj, N; Dutra, ES; Eguchi, H; Eisterer, W; Ekmann, A; Elakkad, A; Evans, WE; Fan, W; Fang, Z; Faria, HP; Farris, SG; Fenoll, J; Fernandez-Botran, R; Flores, P; Fujita, J; Gan, L; Gandara, DR; Gao, X; Garcia, AA; Garrido, I; Gebru, HA; Gerger, A; Germano, P; Ghamande, S; Ghebeh, H; Giver Jensen, T; Go, A; Goichot, B; Goldwater, M; Gontero, P; Greil, R; Gruenberger, B; Guarneri, A; Guo, Y; Gupta, S; Haxholdt Lunn, T; Hayek, AJ; He, ML; Hellín, P; Hepprich, M; Hernández de Rodas, E; Hill, A; Hndeya, AG; Holdsworth, LM; Hookey, L; Howie, W; Hu, G; Huang, JD; Huang, SY; Hubmann, E; Hwang, SY; Imamura, H; Imperiale, A; Jiang, JQ; Jimenez, JL; Jin, F; Jin, H; Johnson, KL; Joseph, A; Juwara, L; Kalapothakis, E; Karami, H; Karayağiz Muslu, G; Kawabata, R; Kerwin, J; Khan, I; Khin, S; Kidanemariam, HG; Kinders, RJ; Klepov, VV; Koehler, S; Korger, M; Kovačić, S; Koyappayil, A; Kroll, MH; Kuban, J; Kummar, S; Kung, HF; Kurokawa, Y; Laengle, F; Lan, J; Leal, HG; Lee, MH; Lemos, KGE; Li, B; Li, G; Li, H; Li, X; Li, Y; Li, Z; Liebl, W; Lillaz, B; Lin, F; Lin, L; Lin, MCM; Lin, Y; Lin, YP; Lipton, RB; Liu, J; Liu, W; Liu, Z; Lu, J; Lu, LY; Lu, YJ; Ludwig, S; Luo, Y; Ma, L; Ma, W; Machado-Coelho, GLL; Mahmoodi, B; Mahoney, M; Mahvash, A; Mansour, FA; Mao, X; Marinho, CC; Masferrer, JL; Matana Kaštelan, Z; Melendez-Araújo, MS; Méndez-Chacón, E; Miletić, D; Miller, B; Miller, E; Miller, SB; Mo, L; Moazzen, M; Mohammadniaei, M; Montaz-Rosset, MS; Mousavi Khaneghah, A; Mühlethaler, K; Mukhopadhyay, S; Mulugeta, A; Nambi, IM; Navarro, S; Nazmara, S; Neumann, HJ; Newman, EM; Nguyen, HTT; Nicolato, AJPG; Nicolotti, DG; Nieva, JJ; Nilvebrant, J; Nocentini, A; Nugent, K; Nunez-Rodriguez, DL; Nygren, PÅ; Oberli, A; Oderda, M; Odisio, B; Oehler, L; Otludil, B; Overman, M; Özdemir, M; Pace, KA; Palm, H; Parchment, RE; Parise, R; Passera, R; Pavlovic, J; Pecherstorfer, M; Peng, Z; Pérez Coll, C; Petzer, A; Philipp-Abbrederis, K; Pichler, P; Piekarz, RL; Pilati, E; Pimentel, JDSM; Posch, F; Prager, G; Pressel, E; Profy, AT; Qi, P; Qi, Y; Qiu, C; Rajasekhar, B; Ramia, JM; Raynor, HA; Reis, VW; Reubi, JC; Ricardi, U; Riedl, JM; Romano, F; Rong, X; Rubinstein, L; Rumboldt, Z; Sabir, S; Safaeinili, N; Sala, BM; Sandoval Castillo, L; Sau, M; Sbhatu, DB; Schulte, T; Scott, V; Shan, H; Shao, Y; Shariatifar, N; Shaw, JG; She, Y; Shen, B; Shernyukov, A; Sheth, RA; Shi, B; Shi, R; Shum, KT; Silva, JC; Singh, A; Sinha, N; Sirajudeen, AAO; Slaven, J; Sliwa, T; Somme, F; Song, S; Steinberg, SM; Subramaniam, R; Suetta, C; Sui, Y; Sun, B; Sun, C; Sun, H; Sun, Y; Supuran, CT; Surger, M; Svartz, G; Takahashi, T; Takeno, A; Tam, AL; Tang, Z; Tanner, JA; Tannich, E; Taye, MG; Tekle, HT; Thomas, GJ; Tian, Y; Tobin, JV; Todd Milne, G; Tong, X; Une, C; Vela, N; Venkateshwaran, U; Villagrán de Tercero, CI; Wakefield, JD; Wampfler, R; Wan, M; Wang, C; Wang, J; Wang, L; Wang, S; Waser, B; Watt, RM; Wei, B; Wei, L; Weldemichael, MY; Wellmann, IA; Wen, A; Wild, D; Wilthoner, K; Winder, T; Wing, RR; Winget, M; Wöll, E; Wong, KL; Wong, KT; Wu, D; Wu, Q; Wu, Y; Xiang, T; Xiang, Z; Xu, F; Xu, L; Yamasaki, M; Yamashita, K; Yan, H; Yan, Y; Yang, C; Yang, H; Yang, J; Yang, N; Yang, Y; Yau, P; Yu, M; Yuan, Q; Zhan, S; Zhang, B; Zhang, H; Zhang, J; Zhang, N; Zhang, Y; Zhao, X; Zheng, BJ; Zheng, H; Zheng, W; Zhou, H; Zhou, X; Zhu, S; Zimmer, DP; Zionts, D; Zitella, A; Zlott, J; Zolfaghari, K; Zuo, D; Zur Loye, HC; Žuža, I | 1 |
| Peard, L; Saltzman, AF; Stark, T; Ziada, A | 1 |
| Abdel Moneim, R; Aldaly, M; Elsherbiny, M; Sakr, A; Shaaban, S | 1 |
| Chen, K; Ding, Y; Dong, Z; Gao, K; Li, R; Li, W; Li, Y; Ma, X; Song, J; Wang, Y; Wang, Z; Yang, X | 1 |
| Chan, W; Chu, SKP; Lee, KCE; Mui, WH; Wong, CSF | 1 |
| Han, Y; Ma, J; Qian, J; Shi, Y; Wang, Y; Yan, X; Yao, N | 1 |
| Agarwal, C; Agarwal, R; Bagby, SM; Dhar, D; Kumar, D; Messersmith, WA; Orlicky, DJ; Pitts, TM; Raina, K; Wempe, MF | 1 |
| Allory, Y; Culine, S; Fléchon, A; Gravis, G; Guy, L; Harter, V; Joly, F; Laguerre, B; Mottet, N; Pfister, C; Soulié, M | 1 |
| Hirabayashi, K; Kikuta, K; Kondo, T; Noguchi, R; Ono, T; Ozawa, I; Sei, A; Yoshimatsu, Y | 2 |
| Fukami, N; Fukaya, K; Ichino, M; Kusaka, M; Nukaya, T; Sasaki, H; Shiroki, R; Sumitomo, M; Takahara, K; Takenaka, M; Zennami, K | 1 |
| Akdogan, B; Akyol, F; Esen, CSB; Hurmuz, P; Kilickap, S; Ozen, H; Ozyigit, G | 1 |
| Alcaraz-Sanabria, A; Burgos, M; Corrales-Sanchez, V; Galan-Moya, EM; Martinez-Canales, S; Montero, JC; Nieto-Jimenez, C; Nuncia-Cantarero, M; Ocaña, A; Pandiella, A | 1 |
| Buffi, N; Casale, P; Colombo, P; Contieri, R; Fasulo, V; Frego, N; Guazzoni, G; Hurle, R; Lazzeri, M; Lughezzani, G; Morenghi, E; Paciotti, M; Saita, A | 1 |
| Dash, A; Diamontopoulos, LN; Gore, JL; Grivas, P; Holt, SK; Lin, DW; Nyame, YA; Psutka, SP; Schade, GR; Winters, BR; Wright, JL; Yu, EY | 1 |
| Deng, ZH; Hong, X; Hou, J; Li, ZX; Pang, LH; Sun, H; Wang, T; Zhang, CY; Zhang, HY; Zhang, J | 1 |
| Gao, W; Li, X; Liu, Y; Luo, D; Yu, L; Yu, X; Zhu, H | 1 |
| Bai, H; Bi, X; Cao, C; Chen, Y; Feng, X; Guan, K; Guan, Y; Hu, L; Hu, Z; Jiang, W; Li, C; Li, Y; Liu, Y; Ma, J; Shi, H; Shou, J; Tian, J; Wang, D; Xiao, Z; Zhang, J; Zhang, W; Zheng, S; Zhou, A | 1 |
| Arora, S; Brown, L; Cai, EY; Corey, E; Garcia, J; Hsieh, AC; Lakely, B; Lam, HM; Lee, JK; Liu, Y; Montgomery, B; Nguyen, HM; Vakar-Lopez, F; Wong, A; Wright, JL | 1 |
| Einama, T; Fujii, Y; Fukai, M; Hatanaka, Y; Kamachi, H; Kawamata, F; Kobayashi, N; Matsuzawa, F; Mizukami, T; Taketomi, A | 1 |
| Bau, L; Browning, RJ; Callan, JF; Elliott, A; Gray, M; Kamila, S; Kiltie, AE; McHale, AP; Ruan, JL; Smart, S; Stride, E; Thompson, J; Vojnovic, B; Yildiz, YO | 1 |
| Cho, YM; Hong, B; Kim, YS; Lee, JL; Lee, Y | 1 |
| Cheon, MJ; Fang, Z; Han, B; Hong, SS; Jung, KH; Kang, YW; Kim, JS; Kim, SJ; Kim, YS; Lee, JE; Lim, JH; Park, JH; Seo, MS; Shin, SM; Son, MK; Woo, MG; Yan, HH; Yoon, YC | 1 |
| Alva, A; Bandini, M; Curran, C; Diamantopoulos, LN; Gallina, A; Grivas, P; Grunewald, CM; Gupta, S; Jain, RK; Lee, JL; McGregor, BA; Mossanen, M; Necchi, A; Niegisch, G; Olson, KM; Pond, GR; Ravi, P; Singh, P; Skelton, WP; Sonpavde, GP; Su, C; Tward, JD | 1 |
| Eurola, A; Haglund, C; Hagström, J; Mustonen, H; Nurmi, AM; Ristimäki, A; Seppänen, H | 1 |
| Bivalacqua, TJ; Brooks, N; Crump, T; DeWolf, WC; Hyndman, ME; Kamat, AM; Kates, M; Lamm, DL; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Steinberg, RL; Thomas, LJ; Vitale, A; Wang, J | 1 |
| Bian, W; Liu, JH; Liu, SG; Lv, HT; Wang, WB; Xing, L; Zhang, TF | 1 |
| Brede, CM; Broekhuizen, HT; Busman, RD; Kuipers, SK; Kuperus, JM; Lane, BR; Noyes, SL; Tobert, CM | 1 |
| Chang, YH; Huang, HS; Lu, MC; Tam, HL | 1 |
| Cao, JX; Lu, FT; Luo, F; Luo, M; Luo, QY; Ma, WJ; Pan, WT; Qiu, MZ; Xia, ZF; Yang, DJ; Zeng, KM; Zhang, L; Zhang, ZH; Zhao, HY; Zhou, T | 1 |
| Adam, AA; Allam, AH; Anderson, KI; Biankin, AV; Boulghourjian, A; Burgess, A; Chantrill, L; Chin, VT; Chou, A; Conway, JR; Cox, TR; Currey, N; Del Monte-Nieto, G; Drury, A; Evans, TR; Froio, D; Gallego-Ortega, D; Gill, AJ; Giry-Laterriere, M; Grey, ST; Harris, NL; Harvey, RP; Herrmann, D; Heu, C; Jain, R; Johns, AL; Kohonen-Corish, M; Lucas, MC; Magenau, A; McCloy, RA; McGhee, EJ; Melenec, P; Morton, JP; Nagrial, AM; Nobis, M; Ormandy, CJ; Pajic, M; Phan, T; Pinese, M; Samra, JS; Samuel, MS; Sansom, OJ; Steinmann, A; Timpson, P; Vennin, C; Walters, SN; Wang, Y; Warren, SC; Weninger, W; Whan, R; Zaratzian, A | 1 |
| Abe, T; Endo, S; Hashizume, M; Iwamoto, C; Koikawa, K; Manabe, T; Miura, D; Miyasaka, Y; Mizumoto, K; Mizuuchi, Y; Moriyama, T; Nagai, E; Nakamura, M; Nakata, K; Oda, Y; Ohtsuka, T; Ohuchida, K; Okumura, T; Sada, M | 1 |
| Chmielowski, B; Dry, SM; Eilber, FC; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Murakami, T; Nelson, SD; Russell, TA; Singh, AS; Unno, M | 1 |
| Chaudhary, AK; Kattel, K; Kumar, V; Mahato, RI; Mondal, G | 1 |
| Bahary, N; Epelboym, I; Hamad, A; Hogg, ME; Lee, KK; Steve, J; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Chen, H; Ji, W; Jin, X; Lin, X; Pan, B; Song, H; Xiao, J; Yu, H | 1 |
| Fujii, Y; Hamada, T; Hiyoshi, M; Imamura, N; Nanashima, A; Tsuchimochi, Y; Wada, T; Yano, K | 1 |
| Li, X; Niu, Q; Song, W; Tian, Z; Wu, J; Xie, M; Xu, Y; Yang, L; Zhang, C; Zhang, Q; Zhao, X; Zhou, B | 1 |
| Akers, N; Albany, C; Bhardwaj, N; Chen, R; Domingo-Domenech, J; Donovan, MJ; Fleming, MT; Galsky, MD; Gnjatic, S; Hahn, NM; Hauke, RJ; Kim-Schulze, S; Losic, B; Oh, WK; Pal, SK; Patel, VG; Schadt, EE; Sfakianos, JP; Sonpavde, G; Starodub, A; Twardowski, P; Uzilov, AV; Wang, H; Yu, M; Zhao, Q | 1 |
| Baiu, I; Charville, GW; Visser, BC | 1 |
| Agrawal, N; Arora, A; Baghmar, S; Bihari, C; Chattopadhyay, TK; Kumar, G; Kumar, S; Pamecha, V; Panda, D; Patidar, Y | 1 |
| Borgmann, H; Cebulla, A; Dogan, S; Frank, T; Hennig, M; Hofbauer, SL; Klatte, T; Kramer, M; Merseburger, AS; Salem, J; Struck, JP | 1 |
| Kawabe, K; Kawamoto, M; Koya, N; Morisaki, T; Nakagawa, S; Nakamura, M; Onishi, H; Tanaka, H; Umebayashi, M | 1 |
| Hou, XF; Li, K; Li, S; Wang, JF; Wu, C; Xu, SN | 1 |
| Ji, M; Lee, EJ; Park, SM; Wang, JH | 1 |
| Brand, TC; Culkin, DJ; Evans, CP; Hafez, KS; Holzbeierlein, JM; Karsh, LI; Koppie, TM; Lerner, SP; Mack, PC; Messing, EM; Plets, M; Sahasrabudhe, DM; Svatek, RS; Tangen, CM; Thompson, IM; Vogelzang, NJ; Wilson, SS; Wood, DP; Wu, G | 1 |
| Huang, M; Huang, Q; Lin, X; Liu, C; Liu, Z; Meng, F; Wang, C; Xie, F | 1 |
| Cheng, L; Li, X; Yang, F; Zhang, L | 1 |
| Basset, V; Cortesse, A; Culine, S; de la Taille, A; Desgrandchamps, F; Dumont, C; Gaudez, F; Masson-Lecomte, A; Meria, P; Meyer, F; Michel, C; Mongiat-Artus, P; Vordos, D | 1 |
| Ichimiya, S; Imaizumi, A; Morisaki, T; Murahashi, M; Nagai, S; Nakamura, K; Ogata, H; Onishi, H; Umebayashi, M; Yamasaki, A; Yanai, K | 1 |
| Einama, T; Kamachi, H; Kamiyama, T; Katoh, N; Mitsuhashi, T; Orimo, T; Sakamoto, Y; Sakata, T; Shibuya, K; Shimada, S; Taketomi, A; Tsuruga, Y; Uchinami, Y; Wakayama, K; Yokoo, H | 1 |
| Hashimoto, K; Itoh, N; Maehana, T; Masumori, N; Nishiyama, N; Okabe, K; Shindo, T; Tachiki, H; Taguchi, K; Takahashi, A; Tanaka, T | 1 |
| Kim, HS; Seo, HK | 1 |
| Berkowitz, RS; Bonventre, JV; Crum, CP; D'Andrea, AD; Decker, B; Do, KT; Feltmate, CM; Hill, SJ; Horowitz, NS; Kochupurakkal, BS; Konstantinopoulos, PA; Liu, JF; Matulonis, UA; Morizane, R; Muto, MG; Nguyen, H; Nucci, MR; Roberts, EA; Shapiro, GI; Swisher, EM; Worley, MJ; Yang, C | 1 |
| Gong, Y; Hao, W; He, B; He, Z; Hu, G; Li, W; Liu, J; Liu, Y; Yu, Q | 1 |
| Jin, R; Wang, GJ; Yan, L; Zhang, M | 1 |
| Chang, HM; Hwang, I; Ip, HNN; Jeong, JH; Kang, J; Kim, KP; Ryoo, BY; Yoo, C | 1 |
| Coen, JJ; Efstathiou, JA; Jani, AB; Kucuk, O; Lautenschlaeger, T; Lee, CT; Parker, W; Rodgers, JP; Sandler, HM; Saylor, PJ; Shipley, WU; Souhami, L; Wu, CL; Zhang, P; Zietman, AL | 1 |
| Lv, C; Wang, J; Wu, N; Yan, S; Yang, Y | 1 |
| Bartsch, JW; Bronsert, P; Conrad, C; Hoeppner, J; Kulemann, B; Lopatta, P; Maurer, J; Nyström, A; Oria, VO; Preca, BT; Schilling, O; Schmitz, T | 1 |
| Cao, S; Han, B; Teng, J; Xu, J; Zhong, H | 1 |
| Barbier, E; Blanc, JF; Bourgeois, V; Desrame, J; Edeline, J; Malka, D; Manfredi, S; Michel, P; Neuzillet, C; Phelip, JM | 1 |
| Ahmmed, B; Faqeer, A; Kampo, S; Khan, M; Kumar, SP; Liu, JW; Yan, Q; Yulin, L | 1 |
| Cao, F; Cao, Y; Fang, F; Jia, Z; Ju, X; Qing, S; Shen, Y; Zhang, H; Zhu, X | 1 |
| Dong, M; Li, X; Sheng, W; Shi, X; Wang, G; Zhou, J | 1 |
| Chen, J; Dai, G; Du, X; Feng, L; Jia, B; Liu, H; Liu, Q; Wang, Y; Wen, K; Yang, Y; Zeng, M; Zhu, Y | 1 |
| Guo, JC; Li, BQ; Liang, ZY; Liu, QF; Seery, S; You, L; Zhang, TP; Zhao, YP | 1 |
| Chen, L; Fang, K; Fang, Z; Liu, T; Wang, L | 1 |
| Harrison, MR; Inman, BA; Meleis, L; Moore, R | 1 |
| Abbott, DE; Ahmad, SA; Dudeja, V; Fields, RC; Franceschi, D; Hawkins, WG; Kim, HJ; Kooby, DA; Lee, RM; Livingstone, AS; Macedo, FI; Maduekwe, U; Maithel, SK; Martin, RCG; Merchant, NB; Patel, SH; Ryon, E; Schwartz, P; Scoggins, CR; Weber, SM; Williams, G | 1 |
| Fang, Z; Fu, B; Hao, P; Xu, J; Yang, Z; Zhou, L | 1 |
| Almasan, A; Dreicer, R; Ecsedy, JA; Hansel, DE; Lindner, D; Mir, MC; Parker, Y; Singh, K; Teh, BT; Zhang, Z; Zhou, N | 1 |
| Chikano, Y; Endo, Y; Higashi, T; Hirose, M; Ishigaki, Y; Kawakami, K; Kitano, A; Minamoto, T; Miyamoto, K; Motoo, Y; Nakada, M; Sai, Y; Sato, H; Shimasaki, T; Takino, T | 1 |
| Bednar, F; Heidt, DG; Lee, CJ; Li, C; Proctor, E; Simeone, DM; Waghray, M; Yalamanchili, M | 1 |
| Huber, KE; Oikonomopoulos, GM; Saif, MW; Syrigos, KN | 1 |
| Barik, S; Gupta, S; Khan, H; Negi, MP | 1 |
| Angspatt, A; Sriussadaporn, S | 1 |
| Chun, F; Gontero, P; Gurioli, A; Kluth, LA; Lucca, I; Marson, F; Martorana, G; Mehnert, A; Oderda, M; Pappagallo, G; Rink, M; Sanguedolce, F; Schiavina, R; Schmid, M; Shariat, SF; Sogni, F | 1 |
| Benson, M; Goldman, B; Lee, CT; Lenz, HJ; Lerner, SP; Petrylak, DP; Sakr, WA; Skinner, EC; Tangen, CM; Thompson, IM; Wilson, SS | 1 |
| Bochner, BH; Chen, LY; Dalbagni, G; Donat, SM; Herr, HW; Sternberg, IA | 1 |
| Singer, A; Tresley, J; Velazquez-Vega, J; Yepes, M | 1 |
| Alva, A; Daignault-Newton, S; Grivas, PD; Hafez, K; Hollenbeck, B; Hussain, M; Lee, CT; Montgomery, JS; Montie, JE; Smith, DC; Weizer, A; Wood, D | 1 |
| Kawamura, N; Matsushita, M; Nin, M; Okada, T; Tsujihata, M; Ujike, T | 1 |
| Arora, S; Bhardwaj, A; Grizzle, WE; McClellan, S; Nirodi, CS; Owen, LB; Piazza, GA; Singh, AP; Singh, S; Srivastava, SK | 1 |
| Baines, AT; Baldwin, AS; Bednarski, BK; Cobb, MG; Gavilano, L; Kim, HJ; Taverna, P; White, CD; Williams, D; Witherspoon, SM; Xu, D | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Muto, T; Nakagawa, N; Sasaki, H; Sudo, T; Sueda, T; Uemura, K; Urabe, K | 1 |
| Bajorin, DF; Bochner, BH; Dalbagni, G; Kent, M; Kim, PH; Sfakianos, JP; Zhao, P | 1 |
| Cass, CE; El-Gehani, F; Ghosh, S; Lai, R; Mackey, JR; North, S; Santos, C | 1 |
| Chang, X; Fan, X; Guo, Q; Huang, Y; Li, X; Lu, J; Lu, Y; Shan, H; Wang, L; Wang, Y; Wang, Z; Zhu, H; Zhu, M; Zhu, S | 1 |
| Baselga, J; Costa, F; Gomez, H; Gradishar, WJ; Hudis, CA; Petrenciuc, O; Rapoport, B; Roche, H; Schwartzberg, LS; Shan, M | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, V; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Somali, I; Tarhan, MO | 1 |
| Castiglioni, V; Cesca, M; Decio, A; Giavazzi, R; Rovida, A; Scanziani, E; Scarlato, V | 1 |
| Atkins, JN; Azar, CA; Biggs, DD; Brufsky, AM; Costantino, JP; Donnellan, PP; Fehrenbacher, L; Geyer, CE; Levine, EA; Mamounas, EP; Northfelt, DW; Paik, S; Polikoff, JA; Provencher, L; Rastogi, P; Robidoux, A; Swain, SM; Tang, G; Wolmark, N; Zapas, JL | 1 |
| Hatakeyama, S; Koie, T; Ohyama, C; Yoneyama, T | 1 |
| Chen, Q; Hu, H; Jiao, D; Song, J; Wu, L; Xu, LQ; Yan, J | 1 |
| Dwinell, MB; Hauser, AD; Roy, I; Williams, CL; Wilson, JM; Zimmerman, NP | 1 |
| Bailey, IS; Byrne, JP; Curtis, NJ; Kelly, JJ; Noble, F; Underwood, TJ | 1 |
| Azria, D; Culine, S; Fenoglietto, P; Pouessel, D; Rebillard, X; Riou, O; Thezenas, S; Thuret, R | 1 |
| Hayashi, H; Kitagawa, H; Makino, I; Miyashita, T; Nakagawara, H; Nakanuma, S; Ohta, T; Sakai, S; Shoji, M; Tajima, H; Takamura, H | 1 |
| Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Kido, M; Ku, Y; Matsumoto, I; Murakami, S; Ohtsubo, I; Okazaki, T; Shinozaki, K; Shinzeki, M; Yoshida, Y | 1 |
| Amano, R; Hirakawa, K; Hirata, K; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Murata, A; Nagahara, H; Ohira, M; Otani, H; Tanaka, H; Toyokawa, T | 1 |
| Funamizu, N; Hiyoshi, Y; Lacy, CR; Parpart, ST; Takai, A; Yanaga, K | 1 |
| Cheng, L; Wang, R; Wang, Z; Wu, Q; Xia, J | 1 |
| Cui, J; Du, Y; Huang, S; Jia, Z; Jiang, W; Kong, X; Li, L; Li, Z; Wei, D; Xie, D; Xie, K | 1 |
| Borazanci, E; Von Hoff, DD | 1 |
| Hara, K; Ishii, T; Kondo, H; Koyama, I; Morita, Y; Suzuki, A; Tashiro, J; Yamaguchi, S | 1 |
| Avan, A; Castellano, L; Fiuji, H; Frampton, AE; Funel, N; Galla, V; Giovannetti, E; Maftouh, M; Pelliccioni, S; Peters, GJ | 1 |
| Anderson, A; Davidenko, I; Deptala, A; Donehower, RC; Dubey, S; Harrison, M; Iveson, T; Jiang, Y; Lakshmaiah, K; Loh, E; Nirni, S; Oliner, KS; Tang, R; Thomas, A; Tjulandin, S; Zhu, M | 1 |
| Andreoli, SC; de Andrade, RV; de Carvalho, GP; Garicochea, B; Gasparini, NJ; Pogue, RE | 1 |
| Bachet, JB; Blanc, JF; Carbonnel, F; Coriat, R; Cueff, A; De La Fouchardière, C; Francois, E; Gauthier, M; Lécaille, C; Malka, D; Manfredi, S; Marthey, L; Sa-Cunha, A; Solub, D; Taieb, J; Terrebonne, E; Thirot Bidault, A; Trouilloud, I | 1 |
| Bekaii-Saab, T; Fogelman, D; Geyer, S; Iyer, R; Ko, AH; Martin, LK; Pant, S; Sommovilla, N; Van Loon, K; Wei, L; Zalupski, M | 1 |
| Guo, Z; Hu, H; Jiao, F; Jin, Z; Wang, L; Yuan, C | 1 |
| Ak, G; Akcay, M; Bayman, E; Etiz, D | 1 |
| Chang, JB; Ding, XX; Jiang, JH; Ma, F; Wang, CP; Wang, N; Wang, QD; Zhang, Y | 1 |
| Asano, E; Funasaka, K; Goto, H; Hamaguchi, M; Hirooka, Y; Hyodo, T; Miyahara, R; Senga, T; Wong, M | 1 |
| Aning, J; Barocas, DA; Bivalacqua, TJ; Black, PC; Campain, NJ; Cookson, MS; Dall'Era, MA; Daneshmand, S; Dinney, CP; Ercole, CE; Espiritu, PN; Fairey, AS; Gandhi, NM; Garcia, JA; Griffin, J; Holzbeierlein, JM; Horenblas, S; Jacobsen, NE; Kassouf, W; Krabbe, LM; Lotan, Y; McGrath, JS; Mertens, LS; Mir, MC; Montgomery, JS; Morgan, TM; North, S; Seah, JA; Shah, JB; Shariat, SF; Spiess, PE; Sridhar, SS; Stephenson, AJ; Thorpe, AC; van Rhijn, BW; Vasdev, N; Wright, JL; Xylinas, E; Youssef, D; Yu, EY; Zargar, H | 1 |
| Christensen, IJ; Hammer, E; Holck, S; Larsson, LI; Nielsen, HJ | 1 |
| Bahra, M; Denkert, C; Dörken, B; Lohneis, P; Oettle, H; Pelzer, U; Riess, H; Sinn, BV; Sinn, M; Stieler, JM; Striefler, JK | 1 |
| Feng, J; Gu, J; Huang, J; Ni, S; Wang, H; Xu, L; Zhang, S; Zhang, W; Zhu, H | 1 |
| Ide, T; Ide, Y; Kai, K; Kitahara, K; Koga, H; Miyoshi, A; Nakamura, H; Nakamura, J; Noshiro, H; Okumura, T | 1 |
| Bilici, A; Demir, N; Dikilitas, M; Oven Ustaalioglu, BB; Selcukbiricik, F; Yildiz, O | 1 |
| Caron, J; Couvreur, P; Desmaële, D; Maksimenko, A; Mougin, J | 1 |
| Cardwell, J; Chatterjee, D; Fleming, JB; Kang, Y; Katz, MH; Li, SQ; Roife, D; Suzuki, R; Thomas, RM; Truty, MJ; Wang, H; Wang, Y; Zhang, R | 1 |
| Duchêne, B; Jonckheere, N; Tréhoux, S; Van Seuningen, I | 1 |
| Aktas, B; Balakan, O; Berk, V; Cinkir, Hy; Demirci, U; Helvaci, K; Kos, T; Kucukoner, M; Oztop, I; Sevinc, A; Tonyali, O; Turan, N; Unal, OU; Yildiz, R; Yilmaz, AU | 1 |
| Guo, Z; Li, X; Su, B; Xie, F; Zhang, M; Zhang, X; Zhou, L | 1 |
| Gao, HQ; Liu, P; Yang, YM; Zhuang, Y | 1 |
| Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL | 1 |
| He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhao, W; Zheng, YB | 1 |
| Barton, S; Edwards, SJ; Thurgar, E; Trevor, N | 1 |
| Jiang, X; Li, B; Wang, J; Xia, N; Yu, Y | 1 |
| Cockerill, PA; Frank, I; Karnes, RJ; Knoedler, JJ; Tarrell, R | 1 |
| Aoki, Y; Furukawa, K; Kagawa, S; Kato, A; Kuboki, S; Miyazaki, M; Ohtsuka, M; Okamura, D; Sakai, N; Shimizu, H; Suzuki, D; Suzuki, T; Takano, S; Takayashiki, T; Yoshitomi, H | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Ohashi, T; Tomimaru, Y; Tomokuni, A; Wada, H | 1 |
| Asaoka, T; Fujitani, K; Fukuda, Y; Haraguchi, N; Hirao, M; Ikeda, M; Miyake, M; Miyamoto, A; Nakamori, S; Nishikawa, K; Omiya, H; Sekimoto, M; Takami, K; Tsujinaka, T; Yamamoto, K | 1 |
| Chen, C; Chen, S; Hou, Y; Li, Y; Wang, R; Wang, X; Wang, Z; Wu, Q; Yang, Q; Yang, Y | 1 |
| Addeo, P; Bachellier, P; Belletier, C; De Blasi, V; Dufour, P; Fuchshuber, P; Oussoultzoglou, E; Rosso, E; Simone, G | 1 |
| Collins, DC; Morris, PG | 1 |
| Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE | 1 |
| Agarwal, N; Bellmunt, J; Berthold, D; Chowdhury, S; Crabb, SJ; Galsky, MD; Harshman, LC; Hussain, SA; Ladoire, S; Milowsky, MI; Moshier, EL; Necchi, A; Pal, SK; Powles, T; Recine, F; Rosenberg, JE; Theodore, C; Vaishampayan, UN; Wong, YN; Yu, EY | 1 |
| Chen, H; Chen, R; Fu, Z; Gao, W; Li, H; Li, W; Li, Z; Liu, Y; Song, Y; Wang, Y; Ye, H; Zeng, J; Zhao, X; Zheng, S; Zhou, Q; Zhou, Y; Zhuang, B | 1 |
| Amano, R; Hirakawa, K; Kimura, K; Motomura, H; Nakata, B; Tanaka, S; Yamamoto, A; Yamazoe, S | 1 |
| Fujino, Y; Goto, H; Hasegawa, H; Kakinoki, K; Katsura, M; Ohara, T; Oshikiri, T; Oyama, M; Sendo, H; Sugimoto, T; Sugiyama, H; Tominaga, M; Ueda, Y; Yamashita, H; Yasuda, T | 1 |
| Ding, Q; Matsubara, S; Miyazaki, Y; Takao, S; Tsukasa, K; Yoshimitsu, M | 1 |
| Boonmars, T; Hahnvajanawong, C; Jearanaikoon, P; Kanchanawat, S; Leelayuwat, C; Namwat, N; Seubwai, W; Techasen, A; Wattanawongdon, W | 1 |
| Huang, CB; Huang, LL; Lin, SJ; Pan, JJ; Qiu, SF; Xu, YJ; Zheng, W; Zong, JF | 1 |
| Beeker, A; Kordes, S; Mathôt, RA; Pollak, MN; Punt, CJ; Richel, DJ; Weterman, MJ; Wilmink, JW; Zwinderman, AH | 1 |
| Hoshino, T; Kodama, R; Mizushima, T; Moritomo, S; Namba, T | 1 |
| Bergman, AM; Bex, A; Horenblas, S; Kerst, JM; Meijer, RP; Mertens, LS; van de Putte, EE; van der Heijden, MS; van der Poel, HG; van Rhijn, BW | 1 |
| Li, H; Li, J; Sun, W; Wang, X; Wei, H; Yi, Z | 1 |
| Bassett, R; Champlin, R; Gulbis, AM; Holmberg, L; Jones, RB; Kingham, A; Ledesma, C; Margolin, K; Nieto, Y; Pagliaro, L; Tannir, N; Tu, SM | 1 |
| Brekken, RA; Dellinger, MT; Dineen, SP; Haaland, G; Kirane, A; Lorens, JB; Ludwig, KF; Micklem, D; Ranaweera, R; Sandal, T; Sorrelle, N; Toombs, JE; Wang, M | 1 |
| Bang, SM; Choi, JY; Choi, SH; Hwang, HK; Kang, CM; Lee, JH; Lee, WJ; Seong, JS | 1 |
| Ding, YC; Huang, T; Luo, SX; Ma, C; Meng, B; Wang, Q; Yu, W | 1 |
| Arriaga, Y; Courtney, K; Krabbe, LM; Lotan, Y; Margulis, V; Raj, GV; Sagalowsky, AI; Westerman, ME | 1 |
| Burki, M; Cohen, SJ; Egleston, B; Hoffman, JP; Meyer, JE; Shaikh, T; Wang, LS | 1 |
| Hashimoto, K; Itoh, N; Shindo, T | 1 |
| Bae, K; Han, SS; Hong, EK; Jung, MK; Kim, TH; Koh, YH; Lee, WJ; Park, SJ; Park, WS; Woo, SM; Yoon, KA | 1 |
| Feng, YH; Huang, KH; Li, CF; Lin, KL; Shen, KH; Tzeng, WS | 1 |
| Guo, J; Tang, N; Wang, Y; Wang, Z; Zhang, Q | 1 |
| Jeong, CW; Kim, HH; Kim, HS; Ku, JH; Kwak, C | 1 |
| Davis, EJ; Griffith, KA; Kim, EJ; McDonnell, KJ; Ruch, JM; Zalupski, MM | 1 |
| Carstens, JL; Kalluri, R; Kaye, J; Kim, J; LeBleu, VS; Scheible, M; Sugimoto, H; Wu, CC; Zheng, X | 1 |
| Dong, Y; Li, D; Li, H; Tian, G; Wang, L; Yuan, Y | 1 |
| Guzzo, T; Keefe, S; Malkowicz, SB; Mamtani, R; Narayan, V; Vaughn, DJ | 1 |
| Dobelbower, MC; Dreicer, R; George, A; Heney, NM; Kaufman, DS; Mitin, T; Sandler, HM; Shipley, WU; Souhami, L; Uzzo, RG; Wallace, HJ; Zietman, AL | 1 |
| Dong, SX; Han, P; Qi, J; Ren, ZG | 1 |
| Baldwin, GS; He, H; Lowy, AM; Nikfarjam, M; Patel, O; Yeo, D | 1 |
| Boegemann, M; Krabbe, LM; Schlack, K; Schrader, AJ; Steinestel, J | 1 |
| Gordetsky, JB; Lockhart, ME; Nix, JW; Sonpavde, G | 1 |
| Amano, K; Ebihara, T; Hiraki, Y; Hoshino, H; Ikeda, N; Inoue, T; Kamigaki, S; Kato, F; Kawada, M; Kimura, Y; Makari, Y; Mikami, J; Munakata, S; Nakata, K; Nakata, Y; Nishi, H; Ohzato, H; Sasamatsu, S; Shimizu, K; Tsujie, M; Yamamoto, T; Yamamura, J; Yoshimura, J | 1 |
| Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Kido, M; Kinoshita, H; Ku, Y; Kuramitsu, K; Matsumoto, I; Matsumoto, T; Takebe, A; Tanaka, M; Terai, S; Toyama, H | 1 |
| Fujiwara, K; Hanaoka, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T | 1 |
| Gehrig, PA; Kim, KH; Milam, B; Palisoul, M; Raker, C; Robison, K; Roque, DR; Taylor, KN; Wysham, WZ | 1 |
| Li, Y; Liu, J; Liu, Y; Qin, S; Su, F; Wang, R; Wang, Z; Wu, Q; Yang, Y; Zhao, F | 1 |
| Fahmy, O; Fend, F; Feyerabend, S; Gakis, G; Scharpf, M; Schubert, T; Schwentner, C; Stenzl, A | 1 |
| Aljarah, AK; Han, B; Ide, H; Inoue, S; Kashiwagi, E; Kawahara, T; Li, Y; Miyamoto, H; Patterson, JD; Shareef, HK; Zheng, Y | 1 |
| Adachi, S; Doi, S; Hirose, Y; Iwashita, T; Kawaguchi, J; Kozawa, O; Moriwaki, H; Nakashima, M; Okuno, M; Shimizu, M; Yasuda, I; Yoshimi, N | 1 |
| Hanvoravongchai, P; Havanond, P; Khempech, N; Luealon, P; Vasuratna, A | 1 |
| Hattori, Y; Inayama, Y; Ishida, H; Kawahara, T; Kondo, T; Kumano, Y; Maeda, Y; Miyoshi, Y; Mochizuki, T; Ohtaka, M; Teranishi, J; Uemura, H; Yao, M; Yumura, Y | 1 |
| Dearnaley, D; Hafeez, S; Hansen, VN; Harris, V; Horwich, A; Huddart, R; Jones, K; Khan, A; Kumar, P; Lalondrelle, S; McDonald, F; McNair, HA; Mohammed, K; Tan, M; Thomas, K; Thompson, A; Warren-Oseni, K | 1 |
| Ishiwata, T; Matsuda, Y; Matsushita, A; Naito, Z; Nakamura, Y; Sumiyoshi, H; Uchida, E | 1 |
| Armbrecht, N; Brooks, J; Calvisi, DF; Ceyhan, GO; Demir, IE; Dombrowski, F; Esposito, I; Fleischmann-Mundt, B; Gürlevik, E; Kleine, M; Kloos, A; Kubicka, S; Kühnel, F; Manns, MP; Oettle, H; Ostroumov, D; Ribback, S; Saborowski, M; Steiger, K; Wirth, TC; Woller, N; Yevsa, T | 1 |
| Chen, H; Deng, X; Gu, J; Li, Y; Peng, C; Shen, B; Shi, M; Wang, D; Wang, X; Wei, G; Zhan, Q; Zhang, J; Zhu, Y | 1 |
| Li, Y; Liu, J; Liu, Y; Ou, W; Su, F; Wang, R; Wang, X; Wu, Q; Zheng, J | 1 |
| Bi, D; Ding, S; Gao, D; Han, L; Li, C; Li, W; Liu, S; Liu, Z; Lu, J; Niu, Z; Yin, L | 1 |
| Akita, H; Fijiwara, Y; Ishikawa, O; Kobayashi, S; Ohigashi, H; Sakon, M; Takahashi, H; Tomokuni, A; Yano, M | 1 |
| Chen, LT; Hsu, MC; Hung, WC; Luo, CW; Pan, MR; Shan, YS | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Iwabuchi, I; Kawaguchi, T; Koie, T; Murasawa, H; Ogasawara, M; Ohyama, C; Yamamoto, H; Yoneyama, T | 1 |
| Chen, ZN; Fu, ZG; Jiang, JL; Li, L; Meng, Y; Wu, B; Wu, XQ; Xu, BQ; Xu, L | 1 |
| Duan, Q; Liu, T; Shen, Q; Wang, C; Wu, H; Yin, T; Zhang, Z; Zhao, H | 1 |
| Chen, W; Hou, H; Li, X; Pan, J; Wu, W; Xue, M; Zhai, W | 1 |
| Korc, M; Kota, J; Kwon, JJ; Quirin, KA; Wek, RC; Willy, JA; Yin, XM | 1 |
| Chen, K; Chen, X; Duan, W; Han, L; Jiang, Z; Lei, J; Li, J; Li, X; Ma, J; Ma, Q; Ma, Z; Sun, L; Wang, F; Wang, Z; Wu, E; Wu, Z; Xu, Q | 1 |
| Cui, H; Jiang, R; Li, X; Lin, X; Liu, C; Tao, R; Tian, S; Zhuang, H; Zhuo, C | 1 |
| Funt, SA; Rosenberg, JE | 1 |
| Fukada, T; Hasegawa, A; Isozaki, M; Kametaka, H; Makino, H; Seike, K | 1 |
| Hoshino, H; Hosoda, Y; Kakita, N; Kawada, J; Kim, Y; Nishino, M; Okano, M; Okuyama, M; Tsujinaka, T; Yamasaki, M | 1 |
| Hirano, Y; Ishii, Y; Kawamoto, S; Maeno, H; Munechika, T; Nomi, M; Noritomi, T; Okamoto, T; Shibata, R; Tanaka, K; Yanagisawa, J; Yonemitsu, Y | 1 |
| Guan, X; Song, W; Tang, L; Wang, S; Xie, H; Xu, J; Xu, Y; Zhang, W | 1 |
| Anandadas, C; Choudhury, A; Elliott, T; Joseph, N; Logue, J; Lyons, J; Sanderson, B; Thompson, C; Wylie, J | 1 |
| Lebret, T | 1 |
| Buclin, T; Chassot, PG; Decosterd, LA; Kuemmerle, A; Lejeune, F; Liénard, D; Mosimann, F; Stupp, R | 1 |
| Cheng, RC; Diao, C; Liu, QY; Su, YJ; Wei, XP; Xu, JB; Zhang, JM | 1 |
| Harada, T; Iwamoto, M; Kimura, K; Nohara, T; Sumiyoshi, K; Takahashi, Y; Tanaka, S; Tanigawa, N | 1 |
| Kato, A; Kimura, F; Miyazaki, M; Nomura, F; Ohtsuka, M; Shida, T; Shimizu, H; Takano, S; Togawa, A; Tomonaga, T; Yoshidome, H; Yoshitomi, H | 1 |
| Nielsen, ME | 1 |
| Bajorin, DF; Bochner, BH; Boyle, MG; Dalbagni, G; Dash, A; Donat, SM; Herr, HW; Milowsky, MI; Pettus, JA; Russo, P | 1 |
| Arumugam, T; Logsdon, CD; Ramachandran, V; Wang, H | 1 |
| Cardenal Escarcena, A; Fernández Sarabia, MT; García Bernardo, L; Rodríguez García, JM; Serrano Vicente, J | 1 |
| Arens, A; Beets, GL; Beets-Tan, RG; Buijsen, J; de Ruysscher, D; Driessen, A; Kessels, AG; Lammering, G; Oellers, M; van Baardwijk, A; Vanhauten, B; Vliegen, RF | 1 |
| El-Baradie, M; Ismail, HM; Khorshid, O; Moneer, M; Touny, A | 1 |
| Heinemann, V | 1 |
| Aoki, T; Hamada, H; Kenno, S; Oba, G; Okuda, K; Shimada, S; Shimokuni, T; Takada, J | 1 |
| Campbell, SC; Dreicer, R; Fergany, AF; Garcia, JA; Gong, MC; Hansel, DE; Jones, JS; Klein, EA; Stephenson, AJ; Weight, CJ | 1 |
| López-Tarruella, S; Rivera, F; Salcedo, M; Vega-Villegas, ME | 1 |
| Barlési, F; Berard, H; Chouaïd, C; Corre, R; Fournel, P; Le Caer, H; Marin, B; Tillon, J; Vergnenègre, A; Vernejoux, JM | 1 |
| Bazan-Perkins, B; Candelaria, M; Cantú, D; Cetina, L; Coronel, J; Dueñas-González, A; Flores, V; Garcia-Arias, A; Gonzalez, A; Rivera, L | 1 |
| Fiorito, C; Gontero, P; Lucca, I; Tizzani, A; Valentino, F | 1 |
| Crawford, ED; deVere White, RW; Goldman, B; Hussain, MH; Lara, PN; Smith, DC; Tangen, CM; Wood, DP | 1 |
| Mizumoto, K; Moriyama, T; Nabae, T; Nagai, E; Ohuchida, K; Sato, N; Takahata, S; Tanaka, M; Toma, H; Yu, J | 1 |
| Al Hasan, SA; Cher, ML; Dickow, B; Eliason, J; Heilbrun, LK; Marur, S; Smith, DW; Vaishampayan, UN | 1 |
| Cheng, AL; Kuo, SH; Lin, ZZ; Yang, SH | 1 |
| Halverson, AL; Hogg, ME; Kiel, KD; Popowich, DA; Stryker, SJ; Wang, EC | 1 |
| Antúnez, A; García-Mata, J; Mellado, JM; Villar, JL; Zambrana, F | 1 |
| Abiko, M; Sato, T; Shiono, S; Tamura, G | 1 |
| Choi, DW; Choi, SH; Heo, JS; Lee, HG; You, DD | 1 |
| Bajorin, DF; Iasonos, A; Maluf, FC; Milowsky, MI; Mironov, S; Nanus, DM; Regazzi, A; Riches, J; Shi, W | 1 |
| Alvarez Sánchez, MV; Alvarez, M; Baltar Arias, R; Gómez Martínez, P; Soto Iglesias, S; Vázquez Astray, E; Vázquez Rodríguez, S | 1 |
| Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, T; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Märten, A; Neugebauer, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C | 1 |
| Bellmunt, J; De Santis, M; de Wit, R; Kerst, JM; Leahy, M; Maroto, P; Marreaud, S; Mead, G; Skoneczna, I; Sylvester, R | 1 |
| Alanko, T; Asola, R; Bono, P; Hahka-Kemppinen, M; Huuhtanen, R; Joensuu, H; Kellokumpu-Lehtinen, P; Kokko, R; Leinonen, M; Pyrhönen, S; Sailas, L; Sunela, K; Turpeenniemi-Hujanen, T; Utriainen, M; Wigren, T | 1 |
| Choi, DW; Choi, SH; Heo, JS; Jun, HJ; Kang, WK; Kim, HS; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS; Yi, SY | 1 |
| Hashiguchi, K; Kitahara, K; Kohya, N; Miyazaki, K; Miyoshi, A; Ohtsuka, T; Yakabe, T | 1 |
| Adab, F; Chau, I; Crellin, A; Cunningham, D; Dunn, J; Eatock, M; Falk, S; Harper, PG; Herrmann, R; Leonard, P; Neoptolemos, JP; Ostrowski, J; Scheithauer, W; Smith, D; Steward, W; Stocken, DD; Thompson, J; Tudur-Smith, C; Valle, JW; West, J | 1 |
| Macarulla, T; Tabernero, J | 1 |
| Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Thomas, K; Watkins, D; Webb, J | 1 |
| Autorino, R; Bruni, G; Cantiello, F; Damiano, R; De Sio, M; Di Lorenzo, G; Federico, P; Gallo, L; Masala, D; Perdonà, S; Pizzuti, M; Quattrone, C | 1 |
| Bruce, JN; Fine, RL; Freda, PU; Isaacson, SR; Lee, Y; Thearle, MS | 1 |
| Groe, R; Grothey, A; Kantelhardt, EJ; Kegel, T; Koelbl, H; Mueller, LP; Schmoll, HJ; Seliger, G; Strauss, HG; Thomssen, C | 1 |
| Cancello, G; Colleoni, M; Montagna, E; Rizzo, S; Scarano, E; Torrisi, R | 1 |
| Alonso, V; Aparicio, J; Arias, F; Escudero, P; Estevan, R; Fernández-Martos, C; Gallen, M; Hernandez, A; Marcuello, E; Massuti, B; Maurel, J; Mengual, JL; Mira, M; Pericay, C; Polo, S; Safont, M; Saigi, E; Salud, A; Serra, J; Vera, R | 1 |
| Rouprêt, M; Yates, DR | 1 |
| Cho, JS; Cho, KS; Chung, BH; Doo, SH; Hong, SJ; Kim, CI; Kim, SJ; Song, KH; Song, YS; Yang, WJ | 1 |
| Batra, SK; Chakraborty, S; Johansson, SL; Mimeault, M; Momi, N; Senapati, S | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Cho, SY; Han, SS; Kim, SH; Kim, TH; Kim, YK; Lee, KW; Lee, WJ; Park, SJ; Woo, SM | 1 |
| Berta, G; Carbone, F; Cattel, L; Fiorito, C; Gontero, P; Medana, C; Milla, P; Paone, TC; Tizzani, A | 1 |
| Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z | 1 |
| Ito, T; Kawashima, H; Nakatani, T; Omachi, T; Tamada, S | 1 |
| Azuma, H; Ibuki, N; Inamoto, T; Katsuoka, Y; Kiyama, S; Komura, K; Kotake, Y; Narumi, Y; Nomi, H; Takahara, K; Ubai, T; Uehara, H; Yamamoto, K | 1 |
| Caffo, O; Fellin, G; Galligioni, E; Graffer, U; Mussari, S; Tomio, L | 1 |
| Abahssain, H; Afchain, P; Errihani, H; Ismaili, N; Melas, N; Rabti, HM; Rahali, R | 1 |
| Ishihara, T; Miyakawa, K; Sakai, Y; Sugiyama, H; Tomizawa, M; Tsuyuguchi, T; Yokosuka, O | 1 |
| Choi, YJ; Chung, JH; Kim, CH; Kim, HR; Lee, CT; Lee, JC; Lee, JS; Rho, JK; Xu, X; Yoon, HI | 1 |
| Bottomley, I; Choudhury, A; Clarke, NW; Cowan, RA; Elliott, PA; Kiltie, AE; Livsey, JE; Logue, JP; Lyons, J; McCaul, D; Ramani, V; Sangar, V; Swindell, R; Symonds, P; Wise, M; Wylie, JP | 1 |
| Aoki, H; Choda, Y; Fujiwara, Y; Harano, M; Matsukawa, H; Ninomiya, M; Nishizaki, M; Ohno, S; Ojima, Y; Shiozaki, S; Takakura, N | 1 |
| Dougal, M; Essapen, S; Gollins, S; Haylock, B; Lloyd, A; Morris, J; Neupane, R; Samuel, L; Saunders, M; Sun Myint, A; Susnerwala, S; Topham, C; Wise, M | 1 |
| Devries, AF; Eisterer, W; Fastner, G; Gnant, M; Greil, R; Jäger, R; Kapp, KS; Keil, F; Offner, F; Ofner, D; Rabl, H; Schaberl-Moser, R; Thaler, J; Tschmelitsch, J; Zitt, M | 1 |
| Dowaki, S; Hirabayashi, K; Imaizumi, T; Makuuchi, H; Matsuyama, M; Okada, K; Tobita, K; Yazawa, N | 1 |
| Arranz, EM; Arranz, MD; Bellido, EC; Cabral, JM; García, AB; Juberías, LA; Kreilinger, JJ; Parga, JM; Prianes, LA; Robledo, JP; Sanz, RR; Sanz-Agero, PG; Serrano, EM | 1 |
| Aboukameel, A; Ali, S; Banerjee, S; Bao, B; Kong, D; Padhye, S; Philip, PA; Sarkar, FH; Sarkar, SH; Wang, Z | 1 |
| Hashimoto, Y; Kobayashi, H; Kondo, N; Murakami, Y; Nakashima, A; Sakabe, R; Sudo, T; Sueda, T; Uemura, K | 1 |
| Avital, I; Davis, JL; Langan, RC; Levy, E; Pandalai, P; Ripley, RT; Steinberg, SM; Toomey, MA; Walker, M | 1 |
| Colaço, A; Lopes, C; Oliveira, PA; Palomino, LF; Santos, L; Vala, H; Vasconcelos-Nóbrega, C | 1 |
| Cabarcas, SM; Farrar, WL; Hurt, EM; Jaffee, EM; Mathews, LA; Zhang, X | 1 |
| Kaneko, G; Kikuchi, E; Matsumoto, K; Miyajima, A; Nakamura, S; Obata, J; Oya, M | 1 |
| Iwaki, R; Motohiro, T; Oishi, M; Yamamichi, K; Yoh, T | 1 |
| Androulakis, N; Boukovinas, I; Constantinides, CA; Georgoulias, V; Karampeazis, A; Kentepozidis, N; Kostakopoulos, A; Kotsakis, A; Markos, V; Mavroudis, D; Papakotoulas, P; Polyzos, A; Samonis, G; Vardakis, N; Ziras, N | 1 |
| Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M | 1 |
| Cao, M; Chen, HG; Ma, CK; Ma, J; Xue, W | 1 |
| Borut, K; Lijana, ZK | 1 |
| Arima, N; Shigaki, N; Sugita, H; Suzuki, S; Yamashita, H; Yokoyama, S | 1 |
| Culine, S; Demery, ME; Pouessel, D; Thézenas, S | 1 |
| Ohlmann, CH; Stöckle, M | 1 |
| Altieri, V; Bono, AV; Brausi, MA; Colombo, R; Conti, I; Gontero, P | 1 |
| Ahmad, A; Ali, S; Azmi, AS; Banerjee, S; Bao, B; Kong, D; Li, Y; Sarkar, FH; Sarkar, SH; Thakur, S; Wang, Z | 1 |
| Doki, Y; Eguchi, H; Gotoh, K; Ishikawa, O; Nagata, S; Ohigashi, H; Takahashi, H; Tomita, Y; Yamada, T; Yano, M | 1 |
| Badalato, GM; Benson, MC; Hruby, G; McKiernan, JM; Petrylak, DP; RoyChoudhury, A; Wosnitzer, MS; Yeshchina, O | 1 |
| Akasu, G; Hisaka, T; Horiuchi, H; Ishikawa, H; Kawahara, R; Kinoshita, H; Kitasato, Y; Mikagi, K; Nakayama, M; Okabe, Y; Yasunaga, M; Yoshitomi, M | 1 |
| Doki, Y; Eguchi, H; Iwagami, Y; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H | 1 |
| Iizawa, H; Kakizaki, Y; Motoi, F; Okada, T; Sakurai, N; Tamura, G; Unno, M; Yamamoto, K | 1 |
| Hashimoto, Y; Hiyama, E; Kondo, N; Murakami, Y; Nakashima, A; Ohge, H; Sakabe, R; Sudo, T; Sueda, T; Uemura, K | 1 |
| Hirai, K; Katoh, R; Ogawa, H; Sunose, Y; Takeyoshi, I; Totsuka, O; Toya, H; Yoshinari, D | 1 |
| Alexander, HR; Funamizu, N; Gaedcke, J; Ghadimi, BM; Hanna, N; Hassan, R; He, P; Hussain, SP; Lacy, C; Lee, DH; Maitra, A; Ried, T; Schetter, A; Yfantis, HG; Zhang, G | 1 |
| Hashmi, A; Masood, R; Qayyum, A; Rafi, M; Tunio, MA | 1 |
| Au-Yeung, G; Davis, ID; Liew, MS | 1 |
| Baselga, J; Bermejo, B; Ciruelos, EM; Costa, F; de Moraes, AA; Del Giglio, A; Durán, MÁ; Espié, M; Filho, SC; Garicochea, B; Gil Gil, M; Gómez, P; Hoff, PM; Kwon Ro, S; Li, S; Llombart, A; Mathias, C; Morales, J; Ojeda, B; Pinczowski, H; Ribeiro, RA; Roché, H; Segalla, JG; Van Eyll, B | 1 |
| Bao, Q; He, B; Pan, Y; Song, G; Tang, Z; Tian, F; Wang, S | 1 |
| Barbachano, Y; Brown, G; Capdevila, J; Cervantes, A; Chau, I; Chua, YJ; Cunningham, D; Dewdney, A; Glimelius, B; Gonzalez de Castro, D; Oates, J; Tabernero, J; Tait, D; Wong, R; Wotherspoon, A | 1 |
| Burkholder, I; Constantin, C; Fritz, E; Gencer, D; Grunewald, M; Hartmann, JT; Hartung, G; Hieber, U; Hipp, M; Hochhaus, A; Hofheinz, RD; Kettner, E; Kienle, P; Kremers, S; Laechelt, S; Lindemann, HW; Link, H; Matzdorff, A; Moehler, M; Müller, L; Post, S; Wenz, F | 1 |
| Lee, JK; Lee, KH; Lee, KT; Moon, IH; Rhee, JC; Yang, MH; Yang, S | 1 |
| Arantes-Rodrigues, R; Cardoso, ML; Colaço, A; Gaivão, I; Oliveira, P; Palmeira, C; Pinto-Leite, R; Santos, L | 1 |
| Alexander, HR; Back, TC; Chan, T; Funamizu, N; Gaedcke, J; Ghadimi, MB; Hanna, N; He, P; Hu, C; Hussain, SP; Lacy, C; Lee, DH; Maitra, A; Ried, T; Schetter, A; Subleski, J; Weiss, JM; Yanaga, K; Yfantis, HG; Zhang, G | 1 |
| Beebe, SJ; Feng, H; Guo, J; Pan, J; Sun, S; Wang, J; Wu, S; Zhang, J | 1 |
| Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B | 1 |
| Pal, SK; Ruel, NH; Wilson, TG; Yuh, BE | 1 |
| Behrman, SW; Chitkara, D; Kumar, V; Mahato, RI; Singh, S | 1 |
| Cheng, S; He, Y; Song, MM; Yuan, HS; Zhong, ZQ | 1 |
| Barrick, B; Fraga, G; Matthys, B | 1 |
| Pal, SK; Ruel, N; Vogelzang, N; Wilson, TG; Yuh, BE | 1 |
| Itoh, K; Matsubara, N; Mukai, H; Naito, Y; Nezu, M | 1 |
| Ai, ZH; Guo, JZ; Liu, WC; Wang, Y; Wen, L; Zhao, SH | 1 |
| Asmar, L; Galsky, MD; Gardner, TA; Hahn, NM; Hellerstedt, BA; Hutson, TE; Kocs, D; Lerner, SP; McKenney, SA; Melnyk, AM; O'Rourke, M; Powles, T; Rauch, M; Sonpavde, G; Vogelzang, NJ; Wang, Y; Yu, M | 1 |
| Boggi, U; Campani, D; Caparello, C; Caponi, S; Cappelli, C; Costa, F; De Lio, N; Falcone, A; Funel, N; Ginocchi, L; Lencioni, M; Lucchesi, M; Mosca, F; Pollina, L; Ricci, S; Vasile, E | 1 |
| Fang, X; Liang, W; Lou, C; Yang, M; Zeng, W; Zhang, C; Zhang, F; Zhang, Y; Zhao, J | 1 |
| Chirita, D; Dumitrascu, T; Ionescu, M; Popescu, I | 1 |
| Ji, S; Liu, C; Long, J; Ni, Q; Xu, J; Xu, W; Xu, Y; Yao, W; Yu, X; Zhang, B; Zhu, W | 1 |
| Bolaños, M; Borrega, P; Castro, J; Dorta, J; Escudero, P; Espinosa, E; Feliu, J; González Barón, M; López Gómez, L; Mel, R; Vázquez-Estévez, SE | 1 |
| Chen, JS; Fung, MC; Hsieh, RK; Wang, CH; Yang, TS | 1 |
| Arquette, MA; Denes, A; Fears, CL; Fracasso, PM; Goodner, SA; Govindan, R; Herzog, TJ; Mutch, DG; Picus, J; Rader, JS; Sun, SL; Tan, BR | 1 |
| Jänicke, F; Jonat, W; Kaufmann, M; Kieback, DG; Kölbl, H; Kuhn, W; Lück, HJ; Mohrmann, S; Reichardt, P; Schindler, AE; Thuss-Patience, PC; Von Minckwitz, G | 1 |
| Arroyo, G; Castagnino, R; Gonzalez Jazey, P; Jaremtchuk, AV; Keropian, M; Mina, C; Zarbá, JJ | 1 |
| Garbrecht, M; Heinemann, V; Helmberger, T; Lamerz, R; Niebler, K; Schalhorn, A; Schermuly, MM; Stemmler, J; Stieber, P; Stoffregen, C; Szymala, AM; Wilkowski, R | 1 |
| Averbuch, SD; Fandi, A; Gatzemeier, U; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Pluzanska, A; Rennie, P; Rosell, R; Scagliotti, G; Schiller, JH; Von Pawel, J; Wolf, MK | 1 |
| Amsellem-Ouazana, D; Beuzeboc, P; Debre, B; Peyromaure, M; Viellefond, A; Zerbib, M | 1 |
| Alloisio, A; Bruzzi, P; Costa, R; Maineri, P; Ratto, GB; Vassallo, G | 1 |
| Edwards, JG; Martin-Ucar, A; O'Byrne, KJ; Pilling, JE; Stewart, DJ; Waller, DA | 1 |
| Esper, P; Fardig, J; Herman, J; Kent, E; Lee, C; Montie, J; Sandler, H; Smith, DC | 1 |
| Hara, I; Kamidono, S; Kawabata, G; Miyake, H; Muramaki, M | 1 |
| Freiha, F; Morgan, K; Srinivas, S | 1 |
| Abbruzzese, JL; Du, M; Lenzi, R; Plunkett, W; Wolff, R; Xiong, HQ | 1 |
| Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Akutsu, Y; Endo, M; Hoshino, T; Matsubara, H; Ochiai, T; Ota, Y; Tsunoda, Y; Yoshinaga, Y | 1 |
| Aitini, E; André, T; de Gramont, A; Ducreux, M; Faroux, R; Hammel, P; Labianca, R; Lepere, C; Lledo, G; Louvet, C; Taïeb, J; Zampino, MG; Zaniboni, A | 1 |
| Futagawa, T; Izumi, H; Miyamoto, H; Oh, T; Sonobe, S; Yamazaki, A | 1 |
| Busby, EM; Carey, D; Divers, SG; Hyatt, MD; Robert, F; Spencer, SA | 1 |
| Montie, JE | 1 |
| Aida, Y; Honma, K; Okura, M; Tanaka, N; Tanimura, S; Tsutsumi, K; Yamamoto, H | 1 |
| Burdick, RK; Cunningham, SC; Cusnir, M; Moesinger, R; Van Echo, DA | 1 |
| Brouwers, MC; Dingle, BH; Rumble, RB | 1 |
| Hyodo, M; Koizumi, M; Kurihara, K; Nagai, H; Sata, N; Shimura, K; Tsukahara, M; Yasuda, Y; Yoshizawa, K | 1 |
| Hada, M; Horiuchi, T; Shinji, H | 1 |
| Cavaglione, G; Chamorey, E; Dides, S; Ferrero, JM; Foa, C; Kaphan, R; Lesbats, G; Nouyrigat, P; Oudard, S | 1 |
| Helke, C; Hoschke, B; May, M | 1 |
| Hu, ML; Yang, TH | 1 |
| Fok, JY; Kumar, R; Manavathi, B; Mann, AP; Mehta, K; Verma, A; Wang, H | 1 |
| Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Yoon, WJ; Yoon, YB | 1 |
| Aleknavicius, E; Asadauskiene, J; Jankevicius, F; Zelviene, TP | 1 |
| Arumugam, T; Logsdon, CD; Ramachandran, V | 1 |
| Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H | 1 |
| Buettner, H; Kaur, H; Marks, RS; Salomao, DR | 1 |
| Amorim, G; Arcuri, RA; Biasoli, I; Djahjah, C; Gaui, MF; Moreira, D; Pereira, G; Spector, N | 1 |
| Altieri, V; Autorino, R; Benincasa, G; D'Armiento, M; De Placido, S; Di Lorenzo, G; Giordano, A; Giuliano, M; Morelli, E; Napodano, G; Russo, A | 1 |
| Alvarez, H; Beaty, R; Bedja, D; Dhara, S; Feldmann, G; Fendrich, V; Gabrielson, KL; Iacobuzio-Donahue, C; Jimeno, A; Karikari, C; Maitra, A; Matsui, W; Mullendore, M | 1 |
| Aerts, JG; Hoogsteden, HC; Senan, S; Surmont, V; Tan, KY; van Klaveren, RJ; van Meerbeeck, JP; van Wijhe, G; Verhoeven, GT; Vernhout, R | 1 |
| Amichetti, M; Caraul, B; Casula, G; Deidda, MA; Dessì, M; Farci, D; Farigu, R; Lay, GC; Maxia, L; Murtas, R; Orrù, S | 1 |
| Fenoglio-Preiser, C; Hingorani, SR; Lowy, AM; Revelo-Penafiel, MP; Thomas, RM; Toney, K; Tuveson, DA; Waltz, SE | 1 |
| Gabata, T; Kayahara, M; Kitagawa, H; Matsui, O; Minato, H; Nakagawara, H; Nakamura, M; Ohnishi, I; Ohta, T; Tajima, H; Takamura, H; Tani, T; Zen, Y | 1 |
| Géczi, L | 1 |
| Burks, T; Chaudhary, UB; Curry, N; Sawhney, R | 1 |
| Dyck, J; Huizing, MT; Schrijvers, D; Specenier, PM; Van den Brande, J; Van den Weyngaert, D; Van Laer, C; Vermorken, JB; Weyler, J | 1 |
| Bajetta, E; Bajetta, R; Celio, L; Colombo, A; Denaro, A; Di Bartolomeo, M; Dotti, K; Ferrario, E; Mancin, M; Pusceddu, S | 1 |
| Doi, T; Fujimi, A; Izumi, K; Kanisawa, Y; Kikuchi, S; Kitahara, T; Ohta, H; Okuda, T; Sato, Y | 1 |
| Gallick, GE; Parikh, NU; Park, SI; Shah, AN; Summy, JM; Zhang, J | 1 |
| Bergmann, F; Büchler, MW; Friess, H; Gaida, MM; Giese, NA; Giese, T; Mayer, C; Michalski, CW; Wente, MN | 1 |
| Hagisawa, S; Hatakeyama, S; Imai, A; Ishimura, D; Iwabuchi, I; Koie, T; Mori, K; Ohyama, C; Okamoto, A; Yamato, T; Yoneyama, T | 1 |
| Carrato, A; Gallego-Plazas, J; Guillén-Ponce, C | 1 |
| Abbruzzese, JL; Chiao, PJ; Fleming, JB; Ishiyama, S; Melisi, D; Sclabas, GM; Tortora, G; Xia, Q | 1 |
| Andreetta, C; Cardellino, GG; Crivellari, D; Damante, G; Di Loreto, C; Lombardi, D; Magri, MD; Mansutti, M; Minisini, AM; Perin, T; Puglisi, F; Russo, S; Veronesi, A | 1 |
| Aparicio, T; Azzedine, A; Bedenne, L; Bonnetain, F; Bosset, JF; Bouché, O; Butel, J; Chauffert, B; Hammel, P; Maingon, P; Mariette, C; Mineur, L; Mornex, F; Rougier, P; Stremsdoerfer, N | 1 |
| Antoine, EC; Khayat, D | 1 |
| Baranov, E; Bouvet, M; Hoffma, RM; Jiang, P; Lee, NC; Moossa, AR; Nardin, S; Rashidi, B; Wang, X; Yang, M | 1 |
| Sun, W; Vaughn, DJ | 1 |
| Baker, CH; Bruns, CJ; Ellis, LM; Fidler, IJ; Killion, JJ; Solorzano, CC; Wood, J | 1 |
| Baldwin, SA; Cass, CE; Clarke, ML; Coupland, RW; Dabbagh, L; Jennings, LL; Koski, SL; Mackey, JR; Santos, CL; Vsianska, M; Young, JD | 1 |
| Ryan, DP; Willett, CG | 1 |
45 review(s) available for deoxycytidine and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Comparative Effectiveness Research; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Outcome Assessment, Health Care; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Recent developments in perioperative combination therapy in muscle-invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Urinary Bladder Neoplasms | 2023 |
Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Eligibility Determination; Female; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2019 |
Salvage Therapy Using Bacillus Calmette-Guérin Derivatives or Single Agent Chemotherapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Invasiveness; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Combination Intravesical Therapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Agents; BCG Vaccine; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Humans; Neoplasm Invasiveness; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Mitomycin; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2020 |
Immune checkpoint inhibitors for urothelial carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Nivolumab; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2018 |
Locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Invasiveness; Organoplatinum Compounds; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2013 |
Primary angiosarcoma of the breast: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Combined Modality Therapy; Deoxycytidine; Developing Countries; Docetaxel; Female; Gemcitabine; Hemangiosarcoma; Humans; Lymph Node Excision; Magnetic Resonance Imaging; Mammaplasty; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Surgical Flaps; Taxoids; Thailand | 2013 |
Unusual aggressive breast cancer: metastatic malignant phyllodes tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Female; Fibroadenoma; Gemcitabine; Humans; Ifosfamide; Muscle Neoplasms; Naphthacenes; Neoplasm Invasiveness; Palliative Care; Phyllodes Tumor; Prognosis | 2013 |
Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Product Surveillance, Postmarketing; Survival Rate; Treatment Outcome | 2014 |
Use of microRNAs in directing therapy and evaluating treatment response in colorectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Chemoradiotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; MicroRNAs; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Resveratrol; Stilbenes | 2014 |
Locally advanced undifferentiated carcinoma with osteoclast-like giant cells of the pancreas.
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Giant Cell; Cell Differentiation; Chemotherapy, Adjuvant; Colectomy; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Mesenteric Vascular Occlusion; Mesenteric Veins; Neoplasm Invasiveness; Osteoclasts; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis | 2015 |
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Gemcitabine; Health Care Costs; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tetrahydroisoquinolines; Topotecan; Trabectedin; Treatment Outcome; United Kingdom | 2015 |
Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Receptors, Vascular Endothelial Growth Factor | 2015 |
Pathological T0 Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Urinary Bladder Neoplasms; Vinblastine | 2016 |
The safety and efficacy of gemcitabine for the treatment of bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Urinary Bladder Neoplasms | 2016 |
Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; BCG Vaccine; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Humans; Isoniazid; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Odds Ratio; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; DNA Repair; Evidence-Based Medicine; Gemcitabine; Humans; Immunotherapy; Lymphatic Metastasis; Muscle Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Organ Sparing Treatments; Preoperative Care; Randomized Controlled Trials as Topic; Time Factors; Urinary Bladder Neoplasms | 2017 |
[Nonmuscle-invasive bladder cancer (NMIBC): when to perform cystectomy?].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Cystectomy; Cystoscopy; Deoxycytidine; Disease Progression; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Patient Selection; Prognosis; Risk Factors; Time Factors; Urinary Bladder Neoplasms | 2008 |
[Medical-oncological aspects in the treatment of pancreatic cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Survival Rate | 2009 |
Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2009 |
New drugs currently available in non-muscle invasive bladder cancer: update on gemcitabine studies.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2008 |
[Virchow's node as the form of onset of squamous cell carcinoma of the pancreas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Palliative Care; Pancreatic Neoplasms; Radiography; Spinal Neoplasms; Vinblastine; Vinorelbine | 2009 |
Failure of bacille Calmette-Guérin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Mitomycin; Neoplasm Invasiveness; Risk Factors; Treatment Failure; Urinary Bladder Neoplasms | 2010 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
[Chemotherapy in gallbladder carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Mitomycin; Neoplasm Invasiveness; Neoplasm Staging; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
[Signet ring cell carcinoma of the ampulla of Vater].
Topics: Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Combined Modality Therapy; Common Bile Duct Neoplasms; Deoxycytidine; Gemcitabine; Humans; Jaundice, Obstructive; Jejunum; Liver; Lymphoma, Follicular; Male; Neoplasm Invasiveness; Neoplasms, Second Primary; Pancreatectomy; Pancreaticoduodenectomy; Splenectomy; Urinary Bladder Neoplasms | 2011 |
Increased expression of DNA repair genes in invasive human pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Databases, Factual; Deoxycytidine; DNA Repair; DNA, Neoplasm; Gemcitabine; Gene Dosage; Gene Expression; Genes, BRCA1; Genomic Instability; Humans; Neoplasm Invasiveness; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Rad51 Recombinase; Spheroids, Cellular | 2011 |
[A case of effective neoadjuvant chemoradiotherapy with capecitabine for locally advanced sigmoid colon cancer].
Topics: Adenocarcinoma; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Positron-Emission Tomography; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2011 |
Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Kidney; Kidney Function Tests; Neoplasm Invasiveness; Paclitaxel; Randomized Controlled Trials as Topic; Urologic Neoplasms; Urothelium | 2012 |
[When should systemic chemotherapy be used for urinary bladder carcinoma?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Guideline Adherence; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2012 |
[A case of intrahepatic cholangiocarcinoma with invasion to right adrenal gland].
Topics: Adrenal Glands; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Tomography, X-Ray Computed | 2011 |
Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Twelve-year experience with left atrial resection in the treatment of non-small cell lung cancer.
Topics: Aged; Arrhythmias, Cardiac; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Heart Atria; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Postoperative Complications; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
[Successful removal of T4 lung cancer with left atrial invasion after induction chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cardiac Surgical Procedures; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Heart Atria; Heart Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pneumonectomy | 2005 |
The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2005 |
[Bladder preservation possibilities in the treatment of muscle-invasive bladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2006 |
[Modern chemotherapy of invasive bladder cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Lymphatic Metastasis; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Pyridines; Survival Analysis | 2008 |
[The role of new drugs in the treatment of locally advanced urothelial tumors of the bladder].
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 1998 |
Adjuvant chemotherapy for muscle-invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2001 |
Management of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Mitomycins; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioisotope Teletherapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Streptozocin | 2002 |
93 trial(s) available for deoxycytidine and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Contact or Invasion to Major Arteries.
Topics: Aged; Aged, 80 and over; Albumins; Arteries; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Vascular Neoplasms | 2021 |
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Urinary Bladder Neoplasms | 2022 |
Re: Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2022 |
The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoplasm Invasiveness; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Sirolimus; TOR Serine-Threonine Kinases; Tumor Microenvironment; Urinary Bladder Neoplasms | 2023 |
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
Topics: Cisplatin; Cystectomy; Deoxycytidine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2023 |
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Nivolumab; Urinary Bladder Neoplasms; Xeroderma Pigmentosum Group D Protein | 2023 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Topics: 3-Hydroxybutyric Acid; Acetazolamide; Acrylates; Administration, Intravenous; Adolescent; Adult; Aerosols; Afghanistan; Aflatoxin M1; Agaricales; Aged; Aged, 80 and over; Agricultural Irrigation; Air Pollutants; alpha-L-Fucosidase; Amino Acid Sequence; Androgen Antagonists; Animals; Antibodies, Bacterial; Antigens, Bacterial; Antineoplastic Agents; Antioxidants; Apoptosis; Artifacts; Autophagy; B7-H1 Antigen; Bacterial Proteins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Bile; Bioelectric Energy Sources; Biosensing Techniques; Body Mass Index; Brain; Brazil; Breast Neoplasms; Bufo arenarum; Burkholderia; C-Reactive Protein; Cadmium; Carbon Compounds, Inorganic; Carbon-13 Magnetic Resonance Spectroscopy; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Carcinoma, Transitional Cell; Case-Control Studies; CD4-Positive T-Lymphocytes; Cell Count; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Characiformes; Child; China; Cities; Cobalt; Colonic Neoplasms; Copper Sulfate; Cross-Sectional Studies; Cyclin-Dependent Kinase Inhibitor p16; Cytokines; Deoxycytidine; Diagnosis, Differential; Digestive System; Dihydroxyphenylalanine; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; DNA Barcoding, Taxonomic; DNA, Bacterial; Dose-Response Relationship, Drug; Down-Regulation; Edetic Acid; Electrochemical Techniques; Electrodes; Embolization, Therapeutic; Embryo, Nonmammalian; Environmental Monitoring; Enzyme-Linked Immunosorbent Assay; Epithelial-Mesenchymal Transition; Fatty Acids; Feces; Female; Follow-Up Studies; Food Contamination; Forkhead Box Protein M1; Fresh Water; Fungicides, Industrial; Gallium Isotopes; Gallium Radioisotopes; Gastrectomy; Gastric Bypass; Gastric Outlet Obstruction; Gastroplasty; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Bacterial; Genetic Markers; Genome, Bacterial; Genome, Mitochondrial; Glioma; Glycogen Synthase Kinase 3 beta; Goats; Gonads; Guatemala; Halomonadaceae; HEK293 Cells; Helicobacter Infections; Helicobacter pylori; Hepacivirus; Histone-Lysine N-Methyltransferase; Hormones; Humans; Hydroxybutyrate Dehydrogenase; Hypersplenism; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Iran; Japan; Lactuca; Laparoscopy; Larva; Ligands; Liver Neoplasms; Lymphocyte Activation; Macrophages; Malaria; Male; Mercury; Metabolic Syndrome; Metals, Heavy; Mice; Middle Aged; Milk, Human; Mitochondria; Models, Molecular; Molecular Structure; Mothers; Multilocus Sequence Typing; Muscles; Mutation; Nanocomposites; Nanotubes, Carbon; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Neuroimaging; Nitriles; Nitrogen Isotopes; Non-alcoholic Fatty Liver Disease; Nuclear Magnetic Resonance, Biomolecular; Obesity; Obesity, Morbid; Oligopeptides; Oxidation-Reduction; Pancreatic Neoplasms; Particle Size; Particulate Matter; Pepsinogen A; Pesticides; Pharmacogenetics; Phosphatidylinositol 3-Kinases; Phospholipids; Phylogeny; Plasmodium ovale; Plasmodium vivax; Platelet Count; Polyhydroxyalkanoates; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postoperative Complications; Pregnancy; Prevalence; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Domains; Proto-Oncogene Proteins c-akt; Proton Magnetic Resonance Spectroscopy; Pseudogenes; PTEN Phosphohydrolase; Pyrazoles; Pyrimidines; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Rats, Long-Evans; Rats, Sprague-Dawley; RAW 264.7 Cells; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, G-Protein-Coupled; Receptors, Urokinase Plasminogen Activator; Recombinant Proteins; Repressor Proteins; Resveratrol; Retrospective Studies; Risk Assessment; Risk Factors; RNA, Messenger; RNA, Ribosomal, 16S; Salinity; Salvage Therapy; Seasons; Sequence Analysis, DNA; Seroepidemiologic Studies; Signal Transduction; Skin; Snails; Soluble Guanylyl Cyclase; Solutions; Spain; Species Specificity; Spheroids, Cellular; Splenic Artery; Stomach Neoplasms; Streptococcus pneumoniae; Structure-Activity Relationship; Sulfonamides; Sunlight; Surface Properties; Surgical Instruments; Surgical Wound Infection; Survival Rate; Tetrahydrouridine; Thinness; Thrombocytopenia; Tissue Distribution; Titanium; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Tumor Microenvironment; Tumor Necrosis Factor-alpha; Turkey; Ubiquinone; Urologic Neoplasms; Viral Envelope Proteins; Wastewater; Water Pollutants, Chemical; Weather; Wnt Signaling Pathway; Xenograft Model Antitumor Assays; Young Adult | 2007 |
Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Oxaliplatin; Prognosis; Prospective Studies; Rectal Neoplasms; Survival Rate; Young Adult | 2020 |
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Seconda
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Perioperative Period; Prospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Prognosis; Prospective Studies; Quality of Life; Remission Induction; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2021 |
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA Damage; DNA Mutational Analysis; Female; Gemcitabine; Humans; Ipilimumab; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Prospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2018 |
Prognostic Factors and the Role of Adjuvant Treatment in Periampullary Carcinoma: a Single-Centre Experience of 95 Patients.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Common Bile Duct Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Papillary; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Incidence; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Sodium Chloride; Urinary Bladder Neoplasms; Urothelium | 2018 |
Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2019 |
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma; Cisplatin; Deoxycytidine; Drug Monitoring; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Neoplasm Invasiveness; Neoplasm Staging; Oxaliplatin | 2019 |
Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Preoperative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Young Adult | 2019 |
Clinical benefits of concurrent capecitabine and cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Quality of Life | 2013 |
The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Quality of Life; Risk Assessment; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2013 |
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms | 2013 |
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
Topics: Administration, Oral; Algorithms; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Dosage Calculations; Female; Fluorouracil; Humans; Neoplasm Invasiveness; Niacinamide; Patient Selection; Phenylurea Compounds; Receptor, ErbB-2; Research Design; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2013 |
Neoadjuvant chemotherapy with gemcitabine plus carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Prospective Studies; Time Factors; Urinary Bladder Neoplasms | 2014 |
Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Organ Sparing Treatments; Survival Rate; Urinary Bladder; Urinary Bladder Neoplasms | 2014 |
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2014 |
Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Risk Assessment; Single-Blind Method; Survival Rate; Treatment Outcome | 2016 |
Timing of thoracic radiotherapy in limited stage small cell lung cancer: results of early versus late irradiation from a single institution in Turkey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Time Factors | 2014 |
α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study.
Topics: Actins; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Stromal Cells; Survival Rate; Tissue Array Analysis; Tumor Microenvironment | 2014 |
Single-Agent versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase II Trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Hepatic Artery; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Single-Blind Method; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Topics: Academic Medical Centers; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Metformin; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Netherlands; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Patient Selection; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2018 |
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lapatinib; Lymph Node Excision; Male; Maximum Tolerated Dose; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Quinazolines; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Consolidation Chemotherapy; Cystectomy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Remission Induction; Salvage Therapy; Urinary Bladder Neoplasms | 2016 |
Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence.
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome; Vascular Neoplasms | 2016 |
Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer.
Topics: Aged; Antineoplastic Agents; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Tolerance; Female; Follow-Up Studies; Gemcitabine; Humans; Longitudinal Studies; Male; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Radiation Dose Hypofractionation; Radiation Injuries; Radiation Tolerance; Survival Rate; Treatment Outcome; United Kingdom; Urinary Bladder Neoplasms | 2017 |
A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.
Topics: Abdominal Cavity; Aged; Antimetabolites, Antineoplastic; Ascites; Blood Gas Analysis; Deoxycytidine; Drug Administration Schedule; Drug Delivery Systems; Extracorporeal Circulation; Female; Gemcitabine; Humans; Hypoxia; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Perfusion | 2009 |
[Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Proportional Hazards Models; Rectal Neoplasms; Retrospective Studies; Survival Rate; Young Adult | 2008 |
Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gastrectomy; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2007 |
A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quality of Life; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2009 |
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Urinary Bladder Neoplasms | 2009 |
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence Intervals; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Prognosis; Prostatectomy; Prostatic Neoplasms; Statistics, Nonparametric; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome | 2009 |
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2009 |
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreas, Exocrine; Pancreatic Neoplasms; Prospective Studies; Quinazolines | 2010 |
Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Analysis; Treatment Outcome; Urologic Neoplasms; Urothelium; Vinblastine | 2009 |
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Radiotherapy Dosage | 2010 |
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Quality of Life; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Time Factors; Treatment Outcome; United Kingdom | 2009 |
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Quinazolines; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Urinary Bladder Neoplasms | 2010 |
Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Risk Factors; Taxoids; Treatment Outcome; Young Adult | 2009 |
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, l
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Digestive System Surgical Procedures; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Medication Adherence; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Rectal Neoplasms; Risk Assessment; Spain; Time Factors; Treatment Outcome | 2010 |
Pharmacokinetic study to optimize the intravesical administration of gemcitabine.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Humans; Hydrogen-Ion Concentration; Neoplasm Invasiveness; Tissue Distribution; Urinary Bladder Neoplasms | 2010 |
Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Care; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Survival Rate; Time Factors; Urinary Bladder Neoplasms | 2011 |
Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscle Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Radiotherapy, Conformal; Urinary Bladder Neoplasms | 2011 |
Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Proportional Hazards Models; Radiation Dosage; Radiotherapy, Adjuvant; Rectal Neoplasms; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United Kingdom | 2011 |
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Conformal; Rectal Neoplasms; Treatment Outcome | 2011 |
Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Embolization, Therapeutic; Gemcitabine; Humans; Maryland; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Research Design; Treatment Outcome | 2011 |
Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscles; Nausea; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Taxoids; Thrombocytopenia; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Leukopenia; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Neutropenia; Paclitaxel; Receptors, Estrogen; Treatment Outcome | 2012 |
[Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2011 |
Phase I study of radiochemotherapy with gemcitabine in invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2012 |
Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Endoscopy; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoplasm Invasiveness; Time Factors; Treatment Outcome; Tumor Burden; Urinary Bladder Neoplasms; Urine | 2011 |
Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Peripheral Nerves; Prognosis; Prospective Studies; Risk Factors | 2012 |
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Brazil; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Sorafenib; Time Factors; Treatment Outcome | 2012 |
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Chemoradiotherapy, Adjuvant; Colectomy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Intestinal Mucosa; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Radiotherapy, Adjuvant; Rectal Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome; United Kingdom | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over Studies; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Radiotherapy Dosage; Rectal Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome | 2012 |
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Proportional Hazards Models; Pyridines; Quinazolines; Survival Analysis | 2012 |
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pyrroles; Sunitinib; Survival Rate; Urinary Bladder Neoplasms; Urothelium | 2013 |
Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Statistics, Nonparametric; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2002 |
Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Hepatocellular; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Analysis; Taiwan; Treatment Outcome | 2002 |
Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome | 2002 |
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2003 |
A phase I-II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 2003 |
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Quinazolines; Reference Values; Survival Analysis; Treatment Outcome | 2004 |
Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2004 |
A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Filgrastim; Fluorouracil; Glucuronates; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pilot Projects; Polyethylene Glycols; Preoperative Care; Prospective Studies; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Treatment Outcome | 2005 |
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis | 2005 |
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a Phase II Hoosier Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Fluorouracil; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2006 |
[Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Function Tests; Kidney Pelvis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Survival Rate; Ureter; Ureteral Neoplasms; Urinary Bladder; Urinary Bladder Neoplasms | 2006 |
A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lymph Node Excision; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Receptors, Estrogen; Receptors, Progesterone | 2007 |
Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Gemcitabine; Humans; Imidazoles; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Pain Measurement; Palliative Care; Prednisone; Probability; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Treatment Outcome; Zoledronic Acid | 2007 |
A phase II study of induction therapy with carboplatin and gemcitabine among patients with locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Denmark; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2006 |
Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Adjuvant; Risk Assessment; Survival Analysis; Time Factors | 2007 |
Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Capecitabine; Colorectal Neoplasms; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Irinotecan; Liver Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Risk Assessment; Survival Analysis; Treatment Outcome | 2007 |
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Carcinoma, Lobular; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Liver Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2008 |
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Infusions, Intravenous; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
263 other study(ies) available for deoxycytidine and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle invasive Bladder Cancer: Con.
Topics: BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
MiR-9-3p regulates the biological functions and drug resistance of gemcitabine-treated breast cancer cells and affects tumor growth through targeting MTDH.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; HEK293 Cells; Humans; Male; Membrane Proteins; Mice, Inbred BALB C; MicroRNAs; Neoplasm Invasiveness; Neoplasm Proteins; Prognosis; RNA-Binding Proteins | 2021 |
ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Movement; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immune Tolerance; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid-Derived Suppressor Cells; Neoplasm Invasiveness; Neoplastic Stem Cells; Prognosis; Recombinant Proteins; Retinal Dehydrogenase; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro.
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2022 |
LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins c-akt; RNA, Long Noncoding; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Y-Box-Binding Protein 1 | 2021 |
Molecular classification of patients with NMIBC predicts the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine-immunohistochemistry-based classification.
Topics: Administration, Intravesical; Anthracyclines; Antibiotics, Antineoplastic; Deoxycytidine; Doxorubicin; Epirubicin; Gemcitabine; Humans; Immunohistochemistry; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study.
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Quality of Life; Urinary Bladder Neoplasms | 2022 |
Serum IL-6 level is associated with clinical outcome of intravesical gemcitabine therapy in T1 non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Interleukin-6; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2022 |
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Carcinoma in Situ; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Novel intravesical gemcitabine delivery system (TAR-200) for neoadjuvant treatment of MIBC: context is everything.
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2022 |
Nonrisk-adapted Sequential Intravesical Gemcitabine and Docetaxel for Nonmuscle-invasive Bladder Cancer: The Time Is Now.
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2023 |
Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial-Mesenchymal Transition: Enhanced Efficacy when Combined with Gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Catechin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Enzyme Stability; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Mice, Inbred C57BL; Neoplasm Invasiveness; Pancreatic Neoplasms; Proteolysis; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Burden | 2019 |
Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Retrospective Studies; Risk Assessment; Survival Analysis; Tertiary Care Centers; Treatment Failure; Treatment Outcome | 2019 |
Conversion surgery for positive peritoneal washing cytology in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Cytodiagnosis; Deoxycytidine; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Peritoneum; Treatment Outcome | 2019 |
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Canada; Cystoscopy; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; United States; Urinary Bladder Neoplasms | 2020 |
International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Decision Rules; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Internationality; Lymph Nodes; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy; Reproducibility of Results; Retrospective Studies | 2020 |
Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Pyridines; Radiotherapy; Retrospective Studies; Tegafur; Time Factors | 2020 |
Recurrent Bladder Cancer in a Teenage Male.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adolescent; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Cystectomy; Cystoscopy; Deoxycytidine; Gemcitabine; Humans; Male; Monitoring, Physiologic; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Progression-Free Survival; Retrospective Studies; Urinary Bladder; Urinary Bladder Neoplasms | 2019 |
MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Cell Movement; Cell Proliferation; Deoxycytidine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Purines; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2020 |
Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Nude; Momordica charantia; Neoplasm Invasiveness; Pancreatic Neoplasms; Plant Extracts; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma.
Topics: Aged; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Depsipeptides; Drug Screening Assays, Antitumor; Drug Tapering; Fibroma; Gemcitabine; Humans; Loss of Function Mutation; Male; Neoplasm Invasiveness; Neurofibromin 1; PTEN Phosphohydrolase; Topotecan | 2021 |
Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Nephroureterectomy; Proportional Hazards Models; Retrospective Studies; Sex Factors; Survival Rate; Ureteral Neoplasms; Vinblastine | 2021 |
Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blood Platelets; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Leukocyte Count; Lymphocytes; Male; Neoplasm Invasiveness; Neutrophils; Platelet Count; Predictive Value of Tests; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Establishment and characterization of NCC-PLPS1-C1, a novel patient-derived cell line of pleomorphic liposarcoma.
Topics: Antineoplastic Agents; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Depsipeptides; Drug Screening Assays, Antitumor; Gemcitabine; Gene Deletion; Genes, Neoplasm; Humans; Liposarcoma; Male; Middle Aged; Neoplasm Invasiveness | 2021 |
Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.
Topics: Apoptosis; Breast Neoplasms; Carboplatin; Caspases; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Neoplasm Invasiveness; Platinum | 2020 |
Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Retreatment; Time Factors; Treatment Failure; Urinary Bladder Neoplasms | 2021 |
Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Medicare; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Social Class; United States; Urinary Bladder; Urinary Bladder Neoplasms | 2021 |
Effects of ER-resident and secreted AGR2 on cell proliferation, migration, invasion, and survival in PANC-1 pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mucoproteins; Neoplasm Invasiveness; Oncogene Proteins; Pancreatic Neoplasms; Proto-Oncogene Mas; Tumor Cells, Cultured | 2021 |
S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Calcium-Binding Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; S100 Proteins; Tissue Array Analysis; Up-Regulation | 2021 |
A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture.
Topics: Animals; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Male; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; Organoids; Urinary Bladder Neoplasms | 2021 |
Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Aggregation; Cell Division; Cell Movement; Cell Self Renewal; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; GPI-Linked Proteins; Humans; Mesothelin; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Organ Size; Pancreatic Neoplasms; Peritoneal Neoplasms; Peritoneum; Peritonitis | 2021 |
Ultrasound-Mediated Gemcitabine Delivery Reduces the Normal-Tissue Toxicity of Chemoradiation Therapy in a Muscle-Invasive Bladder Cancer Model.
Topics: Animals; Antimetabolites, Antineoplastic; Biotinylation; Cell Line, Tumor; Chemoradiotherapy; Contrast Media; Deoxycytidine; Female; Gemcitabine; Humans; Intestines; Mice; Mice, Nude; Microbubbles; Neoplasm Invasiveness; Organs at Risk; Radiation Injuries; Tumor Burden; Ultrasonography; Urinary Bladder; Urinary Bladder Neoplasms | 2021 |
Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2021 |
Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Endocytosis; Endosomes; Epithelial Cell Adhesion Molecule; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Internationality; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Risk Factors; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Retrospective Studies; Risk Assessment; Sialoglycoproteins | 2021 |
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Interferon alpha-2; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms | 2022 |
The effect of gemcitabine combined with AMD3100 applying to cholangiocarcinoma RBE cell lines to CXCR4/CXCL12 axis.
Topics: Benzylamines; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Cholangiocarcinoma; Cyclams; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Receptors, CXCR4 | 2021 |
Comparison of Side Effects and Tolerability Between Intravesical Bacillus Calmette-Guerin, Reduced-Dose BCG and Gemcitabine for Non-Muscle Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Monitoring; Drug Tapering; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Patient Reported Outcome Measures; Prevalence; Symptom Assessment; Urinary Bladder Neoplasms | 2021 |
Gemcitabine-induced Gli-dependent activation of hedgehog pathway resists to the treatment of urothelial carcinoma cells.
Topics: Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glycogen Synthase Kinase 3 beta; Hedgehog Proteins; Humans; Models, Biological; Neoplasm Invasiveness; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Urinary Bladder Neoplasms; Urothelium; Zinc Finger Protein Gli2 | 2021 |
Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; bcl-X Protein; Caspases; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Janus Kinase 2; Models, Biological; Myeloid Cell Leukemia Sequence 1 Protein; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Piperidines; Signal Transduction; Small Molecule Libraries; STAT3 Transcription Factor | 2021 |
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actin Cytoskeleton; Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Biosensing Techniques; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Collagen; Deoxycytidine; Disease Progression; Extracellular Matrix; Gemcitabine; Humans; Liver; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; rho-Associated Kinases; Signal Transduction; src-Family Kinases; Treatment Outcome | 2017 |
Extra-pancreatic invasion induces lipolytic and fibrotic changes in the adipose microenvironment, with released fatty acids enhancing the invasiveness of pancreatic cancer cells.
Topics: Adipose Tissue; Adiposity; Animals; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Fatty Acids; Gemcitabine; Humans; Lipolysis; Mice; Neoplasm Invasiveness; Pancreatic Neoplasms | 2017 |
Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Proliferation; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Imaging, Three-Dimensional; Leiomyosarcoma; Luminescent Proteins; Mice, Nude; Mice, Transgenic; Neoplasm Invasiveness; Red Fluorescent Protein; Stomach Neoplasms; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caveolin 1; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Injections, Intravenous; Ki-67 Antigen; Male; Mice; Micelles; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Pancreatic Neoplasms; Polymers; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Analysis of Perioperative Chemotherapy in Resected Pancreatic Cancer: Identifying the Number and Sequence of Chemotherapy Cycles Needed to Optimize Survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Pancreatic Neoplasms; Perioperative Period; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
Topics: Animals; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Neoplasm Invasiveness; Pancreatic Neoplasms; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Splenic Artery | 2017 |
Pseudolaric Acid B Inhibits Proliferation, Invasion and Epithelial-to-Mesenchymal Transition in Human Pancreatic Cancer Cell.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytokines; Deoxycytidine; Diterpenes; Epithelial-Mesenchymal Transition; Female; Fibronectins; Gemcitabine; Humans; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Signal Transduction; Vimentin | 2018 |
When Lightning Strikes Twice.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Common Bile Duct; Deoxycytidine; Dissection; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Second Primary; Pancreaticoduodenectomy; Reoperation; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Germany; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Practice Patterns, Physicians'; Surveys and Questionnaires; Urinary Bladder Neoplasms; Urology | 2018 |
Combined Gemcitabine and Metronidazole Is a Promising Therapeutic Strategy for Cancer Stem-like Cholangiocarcinoma.
Topics: Aldehyde Dehydrogenase; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cell Transdifferentiation; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Metronidazole; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Spheroids, Cellular | 2018 |
Effects of obatoclax combined with gemcitabine on the biological activity of pancreatic cancer cells under hypoxic conditions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Indoles; Neoplasm Invasiveness; Pancreatic Neoplasms; Pyrroles; Tumor Suppressor Protein p53 | 2018 |
HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasm Invasiveness; Valproic Acid; Vimentin | 2018 |
The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.
Topics: Animals; Bcl-2-Like Protein 11; Benzodiazepines; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice, Nude; Neoplasm Invasiveness; Xenograft Model Antitumor Assays | 2018 |
LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Survival; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Indazoles; Neoplasm Invasiveness; Pancreatic Neoplasms; Piperazines; RNA, Long Noncoding | 2018 |
[Impact of neoadjuvant chemotherapy on the peri-operative morbidity of radical cystectomy for muscle invasive bladder cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Postoperative Complications; Retrospective Studies; Risk Factors; Urinary Bladder Neoplasms | 2018 |
RBPJ and MAML3: Potential Therapeutic Targets for Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Gemcitabine; Hedgehog Proteins; Humans; Immunoglobulin J Recombination Signal Sequence-Binding Protein; Lung Neoplasms; Matrix Metalloproteinases; Neoplasm Invasiveness; Nuclear Proteins; Pancreatic Neoplasms; Receptors, Notch; Signal Transduction; Small Cell Lung Carcinoma; Trans-Activators; Transcription Factors | 2018 |
Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Celiac Plexus; Chemoradiotherapy; Deoxycytidine; Dissection; Female; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2018 |
Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms; Young Adult | 2018 |
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; Deoxycytidine; DNA Repair; DNA Replication; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Culture Techniques; Organoids; Ovarian Neoplasms; Prognosis; Pyrazines; Pyrazoles | 2018 |
Silencing of TRPM8 inhibits aggressive tumor phenotypes and enhances gemcitabine sensitivity in pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Calcium; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Silencing; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; RNA, Small Interfering; TRPM Cation Channels | 2018 |
Resistin effects on pancreatic cancer progression and chemoresistance are mediated through its receptors CAP1 and TLR4.
Topics: Animals; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeletal Proteins; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Humans; Interleukin-6; Mice, SCID; Neoplasm Grading; Neoplasm Invasiveness; Pancreatic Neoplasms; Resistin; STAT3 Transcription Factor; Toll-Like Receptor 4 | 2019 |
Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Platelets; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Inflammation; Liver Neoplasms; Lymphatic Metastasis; Lymphocytes; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neutrophils; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate | 2019 |
ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma.
Topics: ADAM Proteins; Adenocarcinoma; Animals; Basement Membrane; Biocatalysis; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cohort Studies; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Integrins; Lymphangiogenesis; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Neoplasm Grading; Neoplasm Invasiveness; Neovascularization, Pathologic; Paracrine Communication; Signal Transduction | 2019 |
Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pemetrexed; Retrospective Studies; Survival Rate; Vinorelbine | 2019 |
Rg3 inhibits gemcitabine-induced lung cancer cell invasiveness through ROS-dependent, NF-κB- and HIF-1α-mediated downregulation of PTX3.
Topics: A549 Cells; C-Reactive Protein; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; MAP Kinase Signaling System; Neoplasm Invasiveness; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Serum Amyloid P-Component; Signal Transduction | 2019 |
Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Celiac Artery; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiosurgery; Radiotherapy Dosage; Splenic Artery; Time Factors; Treatment Failure; Tumor Burden | 2019 |
Serine/arginine protein-specific kinase 2 promotes the development and progression of pancreatic cancer by downregulating Numb and p53.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Membrane Proteins; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Staging; Nerve Tissue Proteins; Oxaliplatin; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2019 |
WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; RNA, Messenger; Signal Transduction; WT1 Proteins | 2019 |
Antiproliferative Effects of Matricine in Gemcitabine-Resistant Human Pancreatic Carcinoma Cells Are Mediated via Mitochondrial-Mediated Apoptosis, Inhibition of Cell Migration, Invasion Suppression, and Mammalian Target of Rapamycin (mTOR)-TOR/PI3K/AKT S
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lactones; Mitochondria; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sesquiterpenes; Sesquiterpenes, Guaiane; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cause of Death; Combined Modality Therapy; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2019 |
RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Predictive Value of Tests; Random Allocation; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Risk Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2019 |
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
Topics: Aneuploidy; Animals; Apoptosis; Aurora Kinase A; Aurora Kinases; Azepines; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cluster Analysis; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; M Phase Cell Cycle Checkpoints; Mice; Neoplasm Invasiveness; Paclitaxel; Phenotype; Protein Serine-Threonine Kinases; Pyrimidines; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Deoxycytidine; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Immunohistochemistry; Mice; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphorylation; Xenograft Model Antitumor Assays | 2013 |
Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Apoptosis; Carcinoma in Situ; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Silencing; Humans; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; Polycomb Repressive Complex 1; Xenograft Model Antitumor Assays | 2013 |
Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Risk Assessment; Treatment Failure; Urinary Bladder Neoplasms | 2013 |
[Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2013 |
An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.
Topics: Cell Line, Tumor; Cell Movement; Deoxycytidine; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasm Invasiveness; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Receptors, CXCR4; Transcription Factor RelA; Transcription, Genetic; Up-Regulation | 2013 |
Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-Associated Death Protein; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression; Gene Knockdown Techniques; Humans; Imidazoles; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyridazines; RNA, Small Interfering | 2013 |
Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Oxonic Acid; Peripheral Nerves; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2013 |
The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Cystectomy; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Proportional Hazards Models; Retrospective Studies; Smoking; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2014 |
Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Humans; Male; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Nucleoside Transport Proteins; Platinum Compounds; Predictive Value of Tests; Urinary Bladder Neoplasms | 2014 |
Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Knockdown Techniques; HEK293 Cells; Homeodomain Proteins; Humans; Kaplan-Meier Estimate; Mice; Mice, Inbred BALB C; Mice, Nude; Nanog Homeobox Protein; Neoplasm Invasiveness; Neoplasm Transplantation; Neoplastic Stem Cells; Octamer Transcription Factor-3; Pancreatic Neoplasms; RNA Interference; Tumor Burden | 2013 |
Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2013 |
Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Movement; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Indoles; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Topotecan | 2013 |
Downregulation of LIMK1 level inhibits migration of lung cancer cells and enhances sensitivity to chemotherapy drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lim Kinases; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Respiratory Mucosa; RNA, Small Interfering | 2013 |
Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells.
Topics: 1-Methyl-3-isobutylxanthine; Amides; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphodiesterase Inhibitors; Pyridines; Quinolones; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; rhoC GTP-Binding Protein; Vasodilator Agents | 2015 |
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Hospitals, University; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Prospective Studies; Stomach Neoplasms; United Kingdom | 2014 |
[Gemcitabine augments major histocompatibility complex class I-related chain A expression in pancreatic cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Histocompatibility Antigens Class I; Humans; Killer Cells, Natural; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; T-Lymphocytes | 2013 |
[A case of initially unresectable gallbladder cancer with surgical resection after chemotherapy with gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Staging; Remission Induction | 2013 |
[A case of locally advanced pancreatic cancer with hepatic artery invasion treated with neoadjuvant chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2013 |
MicroRNA-301b promotes cell invasiveness through targeting TP63 in pancreatic carcinoma cells.
Topics: Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; NF-kappa B; Pancreatic Neoplasms; Transcription Factors; Tumor Suppressor Proteins | 2014 |
Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasm Invasiveness; Neoplasm Proteins; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Up-Regulation | 2014 |
Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
Topics: Active Transport, Cell Nucleus; Animals; Antibiotics, Antineoplastic; beta Catenin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA Interference; Signal Transduction; Smad4 Protein; Time Factors; Transfection; Up-Regulation | 2014 |
Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Tegafur; Uracil; Young Adult | 2014 |
miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Gemcitabine; Humans; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase | 2014 |
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2015 |
Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax.
Topics: bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Histones; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Tumor Suppressor Protein p53 | 2014 |
FNC, a novel nucleoside analogue, blocks invasion of aggressive non-Hodgkin lymphoma cell lines via inhibition of the Wnt/β-catenin signaling pathway.
Topics: Antineoplastic Agents; Azides; beta Catenin; Cadherins; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lymphoma, Non-Hodgkin; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; RNA, Messenger; Vascular Endothelial Growth Factor A; Wnt Proteins; Wnt Signaling Pathway | 2014 |
Silencing of STRN4 suppresses the malignant characteristics of cancer cells.
Topics: Animals; Anoikis; Calmodulin-Binding Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HCT116 Cells; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms, Experimental; Nerve Tissue Proteins; Pancreatic Neoplasms; RNA, Small Interfering | 2014 |
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Europe; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; North America; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2015 |
IQGAP1 in rectal adenocarcinomas: localization and protein expression before and after radiochemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; ras GTPase-Activating Proteins; Rectal Neoplasms; Young Adult | 2015 |
Involvement of FoxQ1 in NSCLC through regulating EMT and increasing chemosensitivity.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Transcription Factors; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutamates; Guanine; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pemetrexed; RNA, Messenger; Taxoids | 2014 |
Curative resection of gallbladder cancer with liver invasion and hepatic metastasis after chemotherapy with gemcitabine plus S-1: report of a case.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cholecystectomy; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Tegafur | 2014 |
Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Retrospective Studies; Risk Assessment; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Turkey; Young Adult | 2014 |
Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Ki-67 Antigen; Mice; Nanomedicine; Nanoparticles; Neoplasm Invasiveness; Pancreatic Neoplasms; Prodrugs; Squalene; Xenograft Model Antitumor Assays | 2015 |
Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype.
Topics: Animals; Blotting, Western; Cell Culture Techniques; Cell Cycle; Cell Proliferation; Colony-Forming Units Assay; Deoxycytidine; Epithelial-Mesenchymal Transition; Fluorouracil; Gemcitabine; Heterografts; Humans; Immunohistochemistry; Mice; Neoplasm Invasiveness; Pancreatic Neoplasms; Phenotype; Protein Array Analysis; Proteomics; Tumor Cells, Cultured | 2015 |
The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Matrix Metalloproteinase 13; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mucin-1; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt | 2015 |
Prognostic factors and adjuvant treatments for surgically treated cancers of the biliary tract: a multicentre study of the Anatolian Society of Medical Oncology (ASMO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; HMGN Proteins; Humans; Male; MAP Kinase Signaling System; Neoplasm Invasiveness; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; Sequence Analysis, DNA; Trans-Activators | 2015 |
Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2014 |
Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Synergism; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; NF-kappa B; Random Allocation; Signal Transduction; Triterpenes; Xenograft Model Antitumor Assays | 2015 |
Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
[A case of curative resection after downsizing chemotherapy in initially unresectable locally advanced intrahepatic cholangiocarcinoma].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Invasiveness | 2014 |
[A case of initially unresectable pancreatic cancer with arterial invasion successfully resected after chemotherapy].
Topics: Antimetabolites, Antineoplastic; Arteries; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2014 |
[A case of HER2-positive advanced gastric cancer with extensive lymph node metastasis treated via chemotherapy with a trastuzumab-containing regimen followed by conversion surgery].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Stomach Neoplasms; Trastuzumab | 2014 |
The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells.
Topics: Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Hep G2 Cells; Humans; Immunohistochemistry; Liver Neoplasms; Lymphokines; MicroRNAs; Molecular Sequence Data; Neoplasm Invasiveness; Nuclear Proteins; Platelet-Derived Growth Factor; Twist-Related Protein 1; Wound Healing | 2015 |
Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Retrospective Studies; Risk Factors; Splenectomy; Treatment Outcome | 2015 |
Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Failure | 2015 |
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Multicenter Studies as Topic; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2015 |
The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA, Long Noncoding; Survival Analysis | 2015 |
Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celiac Artery; Chemoradiotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Tegafur; Vascular Neoplasms | 2015 |
[A case of stage IV b pancreatic head cancer that was resected because of a good response to chemotherapy].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133(+) pancreatic cancer cells.
Topics: AC133 Antigen; Antigens, CD; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Glycoproteins; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Peptides; Snail Family Transcription Factors; Transcription Factors | 2015 |
Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
Topics: Bile Duct Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Paclitaxel | 2015 |
Analysis on clinical characteristics and influencing factors of patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Risk Factors | 2015 |
Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Snail Family Transcription Factors; Transcription Factors; Up-Regulation; Xenograft Model Antitumor Assays; Zidovudine | 2015 |
Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Expression of XB130 in human ductal breast cancer.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Movement; Cell Proliferation; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mastectomy; MCF-7 Cells; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Risk Factors; RNA Interference; Signal Transduction; Time Factors; Transfection; Treatment Outcome; Up-Regulation | 2015 |
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Child; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Prognosis; Retroperitoneal Neoplasms; Salvage Therapy; Survival Rate; Testicular Neoplasms; Transplantation, Autologous; Young Adult | 2015 |
Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Pancreatic Ductal; Cell Division; Cell Line, Tumor; Cell Movement; Deoxycytidine; Disease Progression; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Specific Pathogen-Free Organisms; Warfarin; Xenograft Model Antitumor Assays | 2015 |
The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Conformal; Retrospective Studies; Treatment Outcome; Veins | 2015 |
MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; Transfection; Up-Regulation | 2015 |
Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carboplatin; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Lymphatic Metastasis; Lymphatic Vessels; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Renal Insufficiency, Chronic; Retrospective Studies; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Cancer Care Facilities; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Radiation Injuries; Radiotherapy, Intensity-Modulated; Regression Analysis; Retrospective Studies; Risk Assessment; Survival Analysis | 2018 |
[EFFICACY OF NEOADJUVANT GEMCITABINE AND CISPLATIN IN THE MANAGEMENT OF MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Muscle, Skeletal; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Urinary Bladder; Urologic Neoplasms | 2015 |
Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Membrane Transport Proteins; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2015 |
An Effective and Well Tolerated Strategy of Bladder Preservation Therapy in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Male; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Nucleoside Transport Proteins; Pancreatic Neoplasms; Snail Family Transcription Factors; Survival Analysis; Transcription Factors; Twist-Related Protein 1 | 2015 |
YAP overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Phenotype; Phosphoproteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Transcription Factors; Up-Regulation; YAP-Signaling Proteins | 2016 |
miR-203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Signal Transduction | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Singapore; Urinary Bladder Neoplasms; Vinblastine | 2015 |
FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Neoplasm Invasiveness; p21-Activated Kinases; Pancreatic Ducts; Pancreatic Neoplasms; Pyridones; Pyrimidines; Xenograft Model Antitumor Assays | 2016 |
[A Case of Invasive Ductal Carcinoma in the Fat Replacement of the Pancreatic Body and Tail].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Fats; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Splenectomy | 2015 |
[A Case of Invasive Intraductal Papillary Mucinous Carcinoma, Penetrating the Stomach, Colon, and Jejunum].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Colon; Deoxycytidine; Drug Combinations; Duodenum; Fatal Outcome; Female; Gemcitabine; Humans; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Stomach; Tegafur | 2015 |
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Taxoids; Uterine Neoplasms | 2016 |
MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Neoplasm Invasiveness; Smad4 Protein | 2016 |
Ten Years of Complete Remission of Pulmonary Metastasis after Post-Cystectomy Palliative Cisplatin-Gemcitabine Chemotherapy with Gefitinib for Muscle Invasive Bladder Cancer: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Quinazolines; Urinary Bladder Neoplasms | 2016 |
Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Interactions; ets-Domain Protein Elk-1; Gemcitabine; Gene Silencing; Humans; Indoles; Male; Neoplasm Invasiveness; Phosphorylation; Prostate; Prostatectomy; Prostatic Neoplasms; Proto-Oncogene Mas; Receptors, Androgen | 2016 |
The significance of phosphorylated heat shock protein 27 on the prognosis of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Male; Middle Aged; Molecular Chaperones; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Phosphorylation; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Topotecan | 2016 |
Invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant, successfully treated by radical cystectomy with adjuvant chemotherapy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2016 |
Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer.
Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Feasibility Studies; Follow-Up Studies; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Organs at Risk; Prospective Studies; Radiation Injuries; Radiation-Sensitizing Agents; Radiography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; bcl-X Protein; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA, Small Interfering; STAT5 Transcription Factor | 2016 |
Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells.
Topics: Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Gemcitabine; Killer Cells, Natural; Mice; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt | 2016 |
GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glial Cell Line-Derived Neurotrophic Factor Receptors; Humans; Kaplan-Meier Estimate; Male; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; PTEN Phosphohydrolase; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden | 2016 |
Nutlin-3 reverses the epithelial-mesenchymal transition in gemcitabine-resistant hepatocellular carcinoma cells.
Topics: Apoptosis; Cadherins; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Imidazoles; Liver Neoplasms; Neoplasm Invasiveness; Piperazines; Smad2 Protein; Snail Family Transcription Factors; Tumor Suppressor Protein p53; Vimentin | 2016 |
CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Deubiquitinating Enzyme CYLD; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Suppressor Proteins; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2016 |
The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Histocompatibility Antigens; Histone Demethylases; Histone-Lysine N-Methyltransferase; Humans; Interleukin-8; Male; Mice; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Pancreatic Stellate Cells; Receptors, Interleukin-8A; RNA, Small Interfering | 2016 |
The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Basigin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gemcitabine; HEK293 Cells; Humans; Immunohistochemistry; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Invasiveness; Pancreas; Pancreatic Neoplasms; Phosphorylation; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Tissue Array Analysis; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice, Nude; NADPH Oxidases; Nanog Homeobox Protein; Neoplasm Invasiveness; Neoplastic Stem Cells; NF-kappa B; Pancreatic Neoplasms; Phenotype; Polycomb Repressive Complex 1; Reactive Oxygen Species; Signal Transduction; SOXB1 Transcription Factors; STAT3 Transcription Factor; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Promoter Regions, Genetic; RNA Interference; RNA, Long Noncoding; Signal Transduction; Time Factors; Transfection; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential.
Topics: Autophagy; Autophagy-Related Proteins; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Membrane Proteins; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; Vesicular Transport Proteins | 2016 |
Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coculture Techniques; Cytokines; Deoxycytidine; Disease Progression; Enzyme Activation; Enzyme Activators; Female; Fibrosis; Gemcitabine; Humans; Metformin; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Pancreatic Stellate Cells; Paracrine Communication; Phosphorylation; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
[Long-Term Survival in Response to Multimodality Therapy in a Patient with Invasive Pancreatic Cancer with Cyst Formation].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cysts; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Time Factors | 2016 |
[A Case of Curatively Resected Locally Advanced Cancer of the Pancreatic Body Treated by Distal Pancreatectomy with En Bloc Celiac Axis Resection after Preoperative Intensive Treatment].
Topics: Aged; Albumins; Celiac Artery; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms | 2016 |
[A Case of Locally Far-Advanced Colon Cancer Resected by Laparoscopic Surgery after Colonic Stent Insertion and Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Ileus; Laparoscopy; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Oxaloacetates; Sigmoid Neoplasms; Stents; Treatment Outcome | 2016 |
PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
Topics: Base Sequence; BRCA1 Protein; Carboplatin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclins; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MicroRNAs; Middle Aged; Mutation; Neoplasm Invasiveness; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms; Up-Regulation | 2017 |
[Clinical effect and positioning of capecitabine for metastatic breast carcinoma].
Topics: Aged; Breast Neoplasms; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Tomography, X-Ray Computed | 2008 |
Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
Topics: Adenocarcinoma; Aged; Annexin A2; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Cell Survival; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Tumor Cells, Cultured | 2008 |
Neoadjuvant gemcitabine and cisplatin: another step on the path toward improving the outcomes of patients with high-risk, invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Risk Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2008 |
Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Mucoproteins; Neoplasm Invasiveness; Oncogene Proteins; Pancreatic Neoplasms; Proteins; RNA Interference; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Adrenal metastasis of breast cancer with involvement of the inferior vena cava.
Topics: Adrenal Gland Neoplasms; Adult; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Mastectomy, Radical; Neoplasm Invasiveness; Radiography; Radiotherapy, Adjuvant; Renal Veins; Vena Cava, Inferior; Venous Thrombosis | 2008 |
Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer?
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fascia; Fasciotomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Image Enhancement; Image Processing, Computer-Assisted; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Rectal Neoplasms; Rectum; Software; Survival Rate; Tomography, X-Ray Computed | 2008 |
[S-1+gemcitabine (GEM) therapy was effective in a case of unresectable pancreatic head carcinoma].
Topics: Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Prohibitins; Tegafur; Tomography, X-Ray Computed | 2008 |
Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Combined Modality Therapy; Cystectomy; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Methotrexate; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Risk Factors; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2009 |
Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIB cervical cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Lymph Nodes; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2009 |
MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance.
Topics: Antimetabolites, Antineoplastic; Cell Line; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A | 2009 |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Glucocorticoids; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy | 2009 |
HIV and anal cancer outcomes: a single institution's experience.
Topics: Antineoplastic Agents; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Colostomy; Deoxycytidine; Female; Fluorouracil; HIV Infections; Humans; Male; Middle Aged; Mitomycin; Mitoxantrone; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Retrospective Studies | 2009 |
Sarcoidosis as a diagnostic pitfall of pancreatic cancer.
Topics: Abdominal Pain; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Carcinoma; Deoxycytidine; Diagnosis, Differential; Fatal Outcome; Female; Gallium Radioisotopes; Gemcitabine; Granuloma; Humans; Laparotomy; Lymph Nodes; Middle Aged; Neoplasm Invasiveness; Palliative Care; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Sarcoidosis; Trigeminal Neuralgia | 2009 |
Malignant solitary fibrous tumor with superior vena cava syndrome.
Topics: Adult; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Lung Neoplasms; Mediastinal Neoplasms; Neoplasm Invasiveness; Pleural Neoplasms; Radiotherapy, Adjuvant; Solitary Fibrous Tumors; Sternum; Superior Vena Cava Syndrome; Tomography, X-Ray Computed; Treatment Outcome; Vascular Surgical Procedures | 2009 |
Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Probability; Prognosis; Proportional Hazards Models; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Survival Analysis | 2009 |
[A case of unresectable hilar bile duct cancer responding to chemo-radiotherapy by gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Duodenal Neoplasms; Fatal Outcome; Female; Gemcitabine; Humans; Lymphatic Metastasis; Neoplasm Invasiveness; Radiography | 2009 |
Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Forecasting; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Patient Selection; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors | 2009 |
Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Invasiveness; Radiography; Temozolomide; Treatment Outcome | 2011 |
Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Papillary; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2010 |
Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms | 2010 |
MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mucin-4; Neoplasm Invasiveness; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms | 2010 |
Adjuvant chemoradiation therapy in gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
[Primary urothelial carcinoma with sarcomatous transformation of the prostate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Sarcoma; Treatment Outcome; Urethral Neoplasms | 2010 |
Novel bladder preservation therapy for locally invasive bladder cancer: combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Balloon Occlusion; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Radiotherapy, Adjuvant; Renal Dialysis; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
[Case of intrahepatic cholangiocarcinoma drained through a fistula of the duodenal bulb].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Duodenal Diseases; Duodenal Neoplasms; Female; Gemcitabine; Humans; Intestinal Fistula; Liver Neoplasms; Neoplasm Invasiveness | 2010 |
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Acinar Cell; Cell Line, Tumor; Cell Movement; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines; Sequence Deletion | 2011 |
[A 6-year survival case of locally advanced unresectable pancreatic tail cancer treated with chemo-radiation therapy].
Topics: Combined Modality Therapy; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Tegafur | 2010 |
Curative surgical treatment after preoperative chemotherapy for primarily inoperable locally advanced pancreatic carcinoma: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Cell Aggregation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clone Cells; Curcumin; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial Cell Adhesion Molecule; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Mice; MicroRNAs; Neoplasm Invasiveness; Neoplasm Proteins; NF-kappa B; Pancreatic Neoplasms; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2011 |
Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate | 2011 |
Experimental study of the anticancer effect of gemcitabine combined with sirolimus on chemically induced urothelial lesions.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Butylhydroxybutylnitrosamine; Deoxycytidine; Gemcitabine; Male; Mice; Mice, Inbred ICR; Neoplasm Invasiveness; Sirolimus; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Muscle Neoplasms; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2011 |
[A resected case of locally invasive rectal cancer successfully treated with neoadjuvant capecitabine, oxaliplatin, bevacizumab and radiation therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Tomography, X-Ray Computed | 2011 |
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Metformin; Mice; Mice, SCID; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Polycomb Repressive Complex 2; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Tumor Stem Cell Assay | 2012 |
Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Doxorubicin; Drug Evaluation; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Proportional Hazards Models; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2012 |
[A case of peritoneal recurrence of invasive carcinoma derived from IPMN after distal pancreatectomy].
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Neoplasms; Recurrence; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of curatively resected locally advanced cancer of the pancreatic body treated by distal pancreatectomy with en bloc celiac axis resection after neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
Prognostic significance of telomerase activity and human telomerase reverse transcriptase expression in ampullary carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Tegafur; Telomerase; Young Adult | 2012 |
[A case of pancreatic cancer with celiac trunk and common hepatic artery invasion successfully resected after gemcitabine+S-1therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Liver; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Cohort Studies; Deoxycytidine; Dipeptidases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genetic Association Studies; GPI-Linked Proteins; Humans; Male; MAP Kinase Signaling System; Maryland; Microtubule-Associated Proteins; Middle Aged; Neoplasm Invasiveness; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Proportional Hazards Models; Reproducibility of Results; Treatment Outcome | 2012 |
Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer: experience at Sindh Institute of Urology & Transplantation (SIUT).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Cystectomy; Cystoscopy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Radiotherapy Dosage; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Pathological responses to gemcitabine/platinum-based neoadjuvant chemotherapy for muscle-invasive urothelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensitivity in pancreatic cancer cells.
Topics: Basigin; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Monocarboxylic Acid Transporters; Muscle Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; RNA Interference; RNA, Messenger; RNA, Small Interfering; Symporters | 2012 |
Guggulsterone enhances antitumor activity of gemcitabine in gallbladder cancer cells through suppression of NF-κB.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Matrix Metalloproteinase 2; Neoplasm Invasiveness; NF-kappa B; Pregnenediones; Vascular Endothelial Growth Factor C | 2012 |
Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Comet Assay; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Gemcitabine; Humans; Mutagens; Neoplasm Invasiveness; Osmolar Concentration; S Phase; Sirolimus; Urinary Bladder Neoplasms | 2012 |
Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Macrophage Migration-Inhibitory Factors; Male; Mice, Nude; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; RNA Interference; Transplantation, Heterologous | 2013 |
Synergistic effects of nanosecond pulsed electric fields combined with low concentration of gemcitabine on human oral squamous cell carcinoma in vitro.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Electric Stimulation Therapy; Gemcitabine; Humans; Mouth Neoplasms; Necrosis; Neoplasm Invasiveness; Time Factors | 2012 |
Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Survival Analysis; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2012 |
miRNA profiling in pancreatic cancer and restoration of chemosensitivity.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Pancreatic Neoplasms | 2013 |
Knockdown of Ezrin by RNA interference reverses malignant behavior of human pancreatic cancer cells in vitro.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Cytoskeletal Proteins; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphorylation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2012 |
Ulcerated plaques in the pelvic region of an adult female.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Genital Neoplasms, Female; Humans; Lapatinib; Middle Aged; Neoplasm Invasiveness; Quinazolines; Skin Neoplasms; Skin Ulcer | 2012 |
Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gemcitabine; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Proportional Hazards Models; RNA, Messenger; Taxoids; Vinblastine; Vinorelbine | 2013 |
Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2013 |
Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells.
Topics: Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Estrogen Antagonists; Flavanones; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphorylation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta; Tumor Cells, Cultured; Wound Healing | 2012 |
Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Inflammation; Male; Middle Aged; Neoplasm Invasiveness; Postoperative Complications; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Up-regulation of MBD1 promotes pancreatic cancer cell epithelial-mesenchymal transition and invasion by epigenetic down-regulation of E-cadherin.
Topics: Adult; Aged; Antigens, CD; Antimetabolites, Antineoplastic; Cadherins; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Nuclear Proteins; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Sirtuin 1; Survival; Transcription Factors; Transcriptional Activation; Twist-Related Protein 1; Up-Regulation | 2013 |
Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Prognosis; Survival Rate; Tomography, X-Ray Computed | 2003 |
Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Receptor, ErbB-2; Urinary Bladder Neoplasms | 2004 |
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Contraindications; Deoxycytidine; Diaphragm; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Mesothelioma; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pericardium; Pleural Neoplasms; Pneumonectomy; Prognosis; Prostheses and Implants; Radiotherapy, Adjuvant; Surgical Mesh; Survival Analysis; Thoracic Surgery, Video-Assisted; Treatment Outcome | 2004 |
Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Division; Cell Line, Tumor; Cell Survival; Cyclohexanes; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Sesquiterpenes; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2004 |
Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Cystitis; Deoxycytidine; Gemcitabine; Hematuria; Humans; Incidental Findings; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Orchiectomy; Positron-Emission Tomography; Prostatectomy; Prostatic Neoplasms; Radiation Injuries; Testicular Neoplasms; Transurethral Resection of Prostate; Ultrasonography; Urinary Bladder Neoplasms; Urinary Diversion | 2004 |
[A case of unresectable advanced pancreatic tail cancer successfully treated with gemcitabine hydrochloride].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Peritoneal Neoplasms; Quality of Life | 2005 |
A case of diffuse pleural mesothelioma in which contralateral exploratory thoracoscopy assisted the selection of therapy.
Topics: Aged; Biopsy, Needle; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Male; Mesothelioma; Neoplasm Invasiveness; Neoplasm Staging; Pleural Effusion, Malignant; Pleural Neoplasms; Risk Assessment; Thoracoscopy; Tomography, X-Ray Computed | 2005 |
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
[An outpatient with unresectable pancreatic cancer treated with gemcitabine showing prolonged NC (22 months)].
Topics: Adenocarcinoma; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Pancreatic Neoplasms | 2005 |
[A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration Schedule; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Peritoneal Neoplasms; Prognosis; Pyrazoles; Remission Induction; Sulfonamides; Thalidomide | 2006 |
Intracellular levels of S-adenosylhomocysteine but not homocysteine are highly correlated to the expression of nm23-H1 and the level of 5-methyldeoxycytidine in human hepatoma cells with different invasion activities.
Topics: Cell Line, Tumor; Deoxycytidine; DNA Methylation; Down-Regulation; Homocysteine; Humans; Liver Neoplasms; Neoplasm Invasiveness; S-Adenosylhomocysteine | 2006 |
Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; GTP-Binding Proteins; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Glutamine gamma Glutamyltransferase 2; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Transglutaminases | 2006 |
Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis | 2006 |
Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Chromatography, Affinity; Cromolyn Sodium; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Reporter; Immunoprecipitation; Luciferases; Mice; Neoplasm Invasiveness; NF-kappa B; Pancreatic Neoplasms; Receptor for Advanced Glycation End Products; Receptors, Immunologic; S100 Proteins | 2006 |
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Taxoids; Vascular Neoplasms | 2006 |
Transcleral orbital invasion by a radiation and chemotherapy-resistant choroidal metastasis of a pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Choroid Neoplasms; Deoxycytidine; Drug Resistance; Eye Enucleation; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Orbital Neoplasms; Radiation Tolerance; Radiotherapy Dosage; Sclera | 2007 |
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Hedgehog Proteins; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Signal Transduction; Tumor Cells, Cultured; Veratrum Alkaloids; Xenograft Model Antitumor Assays | 2007 |
Phase II study of preoperative irradiation and chemotherapy with capecitabine in patients with locally advanced rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Digestive System Surgical Procedures; Feasibility Studies; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Radiotherapy, Adjuvant; Rectal Neoplasms; Treatment Outcome; Vitamin B Complex | 2007 |
The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2007 |
A pure invasive micropapillary carcinoma of the pancreatic head: long disease-free survival after pancreatoduodenectomy and adjuvant chemotherapy with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Duodenum; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms | 2007 |
Locally advanced leiomyosarcoma of the urinary bladder: near-complete pathologic response to neoadjuvant gemcitabine and docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Taxoids; Urinary Bladder Neoplasms | 2007 |
[A case of unresectable advanced pancreatic cancer with peritoneal dissemination responding to continuous dose S-1 monotherapy after chemo-radiation therapy].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Cavity; Peritonitis; Quality of Life; Tegafur | 2007 |
Development and characterization of gemcitabine-resistant pancreatic tumor cells.
Topics: Antimetabolites, Antineoplastic; beta Catenin; Cadherins; Cell Adhesion; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Epithelium; Flow Cytometry; Gemcitabine; Humans; Hyaluronan Receptors; Immunoblotting; Membrane Proteins; Mesoderm; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Tumor Cells, Cultured | 2007 |
CXCL14 expression and potential function in pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Chemokines, CXC; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 2; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA, Messenger; Time Factors; Transcription Factor RelA; Up-Regulation; Vascular Endothelial Growth Factor A | 2008 |
[Short-term outcome of neoadjuvant gemcitabine-carboplatin therapy for muscle-invasive bladder cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Topics: Animals; Anoikis; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Ribonucleotide Reductases; Signal Transduction; Smad2 Protein; Survival Rate; Transforming Growth Factor beta; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Green Fluorescent Proteins; Humans; Luminescent Proteins; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Pancreatic Neoplasms; Tumor Cells, Cultured | 2000 |
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers.
Topics: Affinity Labels; Animals; Antibodies, Monoclonal; Antibody Formation; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Floxuridine; Fluorouracil; Humans; Immunoenzyme Techniques; Membrane Transport Proteins; Mice; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Staging; Thioinosine | 2002 |